SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 1998
Express Scripts, Inc.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as specified in its Charter)
Delaware 0-20199 43-1420563
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of corporation) Identification No.)
14000 Riverport Drive, Maryland Heights, Missouri 63043
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (314) 770-1666
--------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
On February 19, 1998, Express Scripts, Inc. ("Express Scripts") entered
into a Stock Purchase Agreement (the "Stock Purchase Agreement") with
Columbia/HCA Healthcare Corporation ("Columbia"), VH Holdings, Inc. and Galen
Holdings, Inc., pursuant to which Express Scripts will acquire ValueRx, the
pharmacy benefit management business operated by Columbia, for approximately
$445 million in cash. A copy of the Stock Purchase Agreement is filed with this
8-K as Exhibit 2.1 hereto. Consummation of the transaction is subject to the
conditions set forth in the Stock Purchase Agreement, including appropriate
regulatory approvals.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) The following exhibits are filed as part of this report on Form 8-K:
Exhibit 2.1 Stock Purchase Agreement by and among Columbia/HCA Healthcare
Corporation, VH Holdings, Inc., Galen Holdings, Inc. and Express Scripts, Inc.,
dated as of February 19, 1998, and related Schedules (all Schedules, other than
those relating to the calculation of the Purchase Price [as defined therein] are
omitted from this filing, but will be filed with the Commission supplementally
upon request).
Exhibit 99.1 Press release, dated February 20, 1998, by
Express Scripts, Inc.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EXPRESS SCRIPTS, INC.
Date: February 27, 1998 By: /s/ Barrett A. Toan
Barrett A. Toan
President and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
2.1 Stock Purchase Agreement by and among Columbia/HCA Healthcare
Corporation, VH Holdings, Inc., Galen Holdings, Inc. and
Express Scripts, Inc., dated as of February 19, 1998, and
related Schedules (all Schedules, other than those relating to
the calculation of the Purchase Price [as defined therein] are
omitted from this filing, but will be filed with the
Commission supplementally upon request).
99.1 Press release, dated February 20, 1998, by Express Scripts,
Inc.
EXHIBIT 99.1
EXPRESS SCRIPTS ANNOUNCES AGREEMENT
TO PURCHASE VALUERX FROM COLUMBIA/HCA
$445 MILLION TRANSACTION WILL CREATE LARGEST INDEPENDENT PBM
MANAGING MORE THAN $4.0 BILLION IN DRUG CLAIMS
ST. LOUIS, February 20, 1998 - Express Scripts, Inc. (NASDAQ:ESRX) today
announced that it has executed a definitive agreement to purchase ValueRx, the
pharmacy benefit management (PBM) subsidiary of Columbia/HCA Healthcare
Corporation (NYSE:COL). The transaction will make Express Scripts the largest
PBM independent of drug manufacturer ownership. The combination will enhance
Express Scripts' ability to meet the needs of clients and their participants,
while offering greater resources in advanced clinical, consultative and
information services.
Under the terms of the definitive agreement, Express Scripts will purchase
ValueRx from Columbia/HCA for approximately $445 million in cash. This
transaction will increase network claims processed by approximately 75 percent
and would more than double mail service prescriptions processed annually. In
1997, the combined revenue of the two companies was in excess of $2.7 billion
and the combined managed annual prescription drug spend was more than $4.0
billion.
"We are confident that combining the industry expertise from ValueRx with
that of Express Scripts will create a stronger, more competitive healthcare
management company," says Barrett Toan, president and chief executive officer of
Express Scripts. "By growing in size and strength, we will be able to offer
enhanced services and generate significant economies of scale, increasing our
value to customers, employees and shareholders."
Historically, the two companies have served different market segments.
ValueRx's customer base is comprised predominantly of employer groups, including
a number of Fortune 1000 companies, and indemnity insurance carriers. Express
Scripts has focused on smaller group plans by building strong relationships with
third-party administrators and select managed care organizations. This
transaction brings together the unique strengths in serving these distinctly
different markets and provides the company with the resources and experience to
pursue new business in both segments.
"We place great importance on ValueRx's expertise in the employer group
market," says Toan. He explained that clients will now have access to a broad
spectrum of healthcare management services to improve the quality and cost of
healthcare for their members. Specifically, he cited the benefits of additional
mail service and call center capacity, increased access for clients and members
to pharmacies and expanded opportunities to work with pharmaceutical
manufacturers to optimize contracting and coordinate formularies over a broader
book of business.
Kevin Roberg, president and CEO of ValueRx, states, "Over the past two
years, the employees of ValueRx have worked hard to maintain high standards for
quality service, and this transaction will allow them to continue their
dedication to our customers and our commitment to product innovation and
growth."
Additionally, the combination of Express Scripts and ValueRx will allow
increased investment in new products and services, including industry-leading
clinical services, formulary management and provider profiling capabilities.
"Through Express Scripts' subsidiary Practice Patterns Science, clients of the
combined company will have access to integrated medical information which can be
used to better manage healthcare quality and costs," adds Barrett Toan,
"ValueRx's proprietary data warehouse and data mining technology also provides
clients with capabilities to measure healthcare outcomes."
Completion of the transaction is subject to customary closing conditions,
including required governmental approvals, expiration of the requisite waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of
funds by Express Scripts under a bank facility to be arranged by BT Alex. Brown
& Sons Incorporated, Express Scripts' financial advisor in the transaction.
Express Scripts expects the transaction will be completed in the second quarter
of 1998. The company anticipates that the combination will not be dilutive to
earnings per share in 1998 and will be accretive to earnings per share in 1999.
Express Scripts, Inc. is a leader in healthcare management, delivering
advanced capabilities in several complementary healthcare businesses. Express
Scripts' pharmacy benefit management business currently provides managed
prescription drug services to more than 12.3 million members in the United
States and Canada and has received the highest ranking for overall customer
satisfaction in the last two annual Pharmacy Benefit Management Institute
surveys. Practice Patterns Science, Inc. offers healthcare information
management services, linking healthcare data from all points of care. ESI Vision
Care is the company's eyecare management business. IVTx applies managed care
principles to infusion therapy management. Health Management Services provides
comprehensive informed decision counseling and disease management services
through a 24-hour call center staffed by nurses and pharmacists. Express
Scripts' businesses serve HMOs, third-party administrators, insurance companies,
unions and self-insured employers. Express Scripts is headquartered in St.
Louis.
ValueRx is a leader in pharmacy benefit management services and develops
clinical programs designed to positively impact patient care, while managing
overall healthcare costs. ValueRx provides its services to employers, unions,
managed care organizations, BlueCross and BlueShield plans, insurance carriers
and public sector clients.
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING BUT NOT
LIMITED TO STATEMENTS RELATED TO THE COMPANY'S PLANS, OBJECTIVES, EXPECTATIONS
(FINANCIAL AND OTHERWISE) OR INTENTIONS. THESE STATEMENTS INVOLVE RISKS AND
UNCERTAINTIES THAT MAY CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER
SIGNIFICANTLY FROM THOSE PROJECTED OR SUGGESTED. FACTORS THAT MAY IMPACT THESE
FORWARD-LOOKING STATEMENTS INCLUDE HIGHER THAN EXPECTED COSTS IN INTEGRATING AND
OPERATING THE COMBINED COMPANY; LOSS OF CLIENTS IN THE TRANSITION PROCESS; LOWER
THAN EXPECTED SALES AND REVENUE GROWTH; HEIGHTENED COMPETITION; CHANGES IN
PRICING OR DISCOUNT PRACTICES OF PHARMACEUTICAL MANUFACTURERS; THE ABILITY OF
THE COMPANY TO CONSUMMATE CONTRACT NEGOTIATIONS WITH PROSPECTIVE CLIENTS;
COMPETITION IN THE BIDDING AND PROPOSAL PROCESS; ADVERSE RESULTS IN CERTAIN
LITIGATION AND REGULATORY MATTERS; THE ADOPTION OF ADVERSE LEGISLATION OR A
CHANGE IN THE INTERPRETATION OF EXISTING LEGISLATION OR REGULATIONS; RISKS
ASSOCIATED WITH THE DEVELOPMENT OF NEW PRODUCTS; AND OTHER RISKS DESCRIBED FROM
TIME TO TIME IN THE COMPANY'S PUBLIC FILINGS WITH THE SECURITIES AND EXCHANGE
COMMISSION.
EXHIBIT 2.1
STOCK PURCHASE AGREEMENT
by and among
COLUMBIA/HCA HEALTHCARE CORPORATION,
VH HOLDINGS, INC.,
GALEN HOLDINGS, INC.
and
EXPRESS SCRIPTS, INC.
Dated as of February 19, 1998
<PAGE>
TABLE OF CONTENTS
ARTICLE I DEFINITIONS 1
ARTICLE II PURCHASE AND SALE; CLOSING
2.1 Sale of the Shares
2.2 Excluded Assets and Liabilities; Certain Included Liabilities
2.3 Purchase Price
2.4 Closing
2.5 Closing Deliveries
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLERS
3.1 Organization of Columbia, Holdings and Galen
3.2 Organization and Capitalization of Value Health and MPN
3.3 Organization and Capitalization of the Value Health Subsidiaries
3.4 Corporate Authorization
3.5 No Conflicting Agreements; Consents
3.6 Financial Statements
3.7 Absence of Undisclosed Liabilities
3.8 Absence of Certain Changes
3.9 Legal Proceedings, etc
3.10 Certain Contracts
3.11 Title to Property
3.12 Employees; Labor Matters; Employee Benefit Plans; ERISA
3.13 Bank Accounts
3.14 Taxes
3.15 Insurance
3.16 Intellectual Property
3.17 Compliance with Laws
3.18 Environmental Conditions
3.19 Brokers
3.20 Operations of the Acquired Entities and the Excluded Subsidiaries
3.21 AT&T Contract
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER
4.1 Organization
4.2 Corporate Authorization
4.3 No Conflicting Agreements; Consents
4.4 Legal Proceedings, etc
4.5 Brokers
4.6 Investment Representations
4.7 Financing
ARTICLE V COVENANTS OF SELLERS
5.1 Regulatory Approvals
5.2 Conduct Prior to the Closing
5.3 Employee Matters
5.4 Investigation by Purchaser
5.5 Financial Statements and Reports
5.6 Closing Conditions
5.7 Material Contracts; Transactions with Affiliates
5.8 Transfer of Assets
5.9 Encumbrances
5.10 Condition of Assets
5.11 Consultative Process
5.12 Intercompany Accounts
5.13 Notice of Certain Occurrences
5.14 Exclusivity
5.15 Resignations
5.16 Post Closing Non-Competition
5.17 Sellers' Non-Solicitation
5.18 Columbia Confidentiality Agreements
ARTICLE VI COVENANTS OF PURCHASER; CERTAIN ADDITIONAL COVENANTS OF THE PARTIES
6.1 Confidentiality
6.2 Regulatory Approvals
6.3 Books and Records
6.4 Closing Conditions
6.5 Notice of Certain Occurrences
6.6 Employee Matters
6.7 WARN Act Compliance
6.8 Tax Matters
6.9 Purchaser's Non-Solicitation
6.10 Financing
ARTICLE VII CONDITIONS TO OBLIGATIONS OF PURCHASER
7.1 Representations and Warranties
7.2 Compliance with Agreement
7.3 Closing Certificates
7.4 Secretary's Certificates
7.5 Opinion of Counsel
7.6 Consents, Authorizations, Etc.
7.7 No Action or Proceeding
7.8 Certificates of Incorporation; Bylaws
7.9 Resignation of Boards of Directors and Officers
7.10 Good Standing Certificates
7.11 Material Adverse Change
7.12 Waiver of Conditions
7.13 Trademark Acknowledgment Agreement
7.14 Columbia PBM Agreement
7.15 Financing
7.16 MedManagement Agreement
ARTICLE VIII CONDITIONS TO OBLIGATIONS OF SELLERS
8.1 Representations and Warranties
8.2 Compliance with Agreement
8.3 Closing Certificates
8.4 Secretary's Certificate
8.5 Opinion of Counsel
8.6 Consent, Authorizations, Etc.
8.7 No Action or Proceeding
8.8 Good Standing Certificate
8.9 Certificate of Incorporation; Bylaws
8.10 Waiver of Conditions
8.11 Trademark Acknowledgment Agreement
8.12 MedManagement Agreement
ARTICLE IX INDEMNIFICATION
9.1 Indemnification by Sellers
9.2 Indemnification by Purchaser
9.3 Claims Procedures
9.4 Limitations on Claims
9.5 Insured Losses
ARTICLE X TERMINATION
10.1 Termination Events
10.2 Effect of Termination
ARTICLE XI NOTICES
11.1 Notices
ARTICLE XII MISCELLANEOUS
12.1 Fees and Expenses
12.2 Entire Agreement
12.3 Waiver
12.4 Amendment
12.5 Counterparts; Facsimile Signatures
12.6 No Third Party Beneficiary
12.7 GOVERNING LAW, CONSTRUCTION
12.8 Binding Effect
12.9 No Assignment
12.10 Headings, Gender, Etc.
12.11 Public Announcement
12.12 Access to Information
12.13 Severability; Invalid Provisions
12.14 Cooperation
12.15 Further Assurance Clause
<PAGE>
STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT ("AGREEMENT") is made and entered into as of
February 19, 1998, by and among COLUMBIA/HCA HEALTHCARE CORPORATION, a Delaware
corporation ("COLUMBIA"), VH HOLDINGS, INC., a Nevada corporation ("HOLDINGS"),
GALEN HOLDINGS, INC., a Nevada corporation ("GALEN"), and EXPRESS SCRIPTS, INC.,
a Delaware corporation ("PURCHASER"). Columbia, Holdings and Galen are
hereinafter referred to collectively as the "SELLERS".
R E C I T A L S:
WHEREAS, Holdings is a wholly-owned subsidiary of Columbia; and
WHEREAS, Galen is an indirect wholly-owned subsidiary of Columbia; and
WHEREAS, Holdings owns 100% of the issued and outstanding shares (as
further defined in Section 3.2(a)(ii), the "VALUE HEALTH SHARES") of capital
stock of Value Health, Inc., a Delaware corporation ("VALUE HEALTH"); and
WHEREAS, Galen owns 100% of the issued and outstanding shares (as further
defined in Section 3.2(b)(ii), the "MPN SHARES") of capital stock of Managed
Prescription Network, Inc., a Delaware corporation ("MPN"); and
WHEREAS, Holdings and Galen wish to sell all of the Value Health Shares and
all of the MPN Shares respectively, to Purchaser, and Purchaser wishes to
purchase all of the Value Health Shares and the MPN Shares from Holdings and
Galen respectively, on the terms, subject to the conditions and for the
consideration set forth in this Agreement; and
WHEREAS, Columbia will derive material benefits from the consummation of
the transactions contemplated hereby, and wishes to enter into this Agreement as
an inducement to the other parties to enter into this Agreement;
NOW, THEREFORE, in consideration of the foregoing premises, the mutual
covenants and other agreements set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto covenant and agree as follows:
ARTICLE I
DEFINITIONS
As used in this Agreement, the following defined terms shall have the
meanings indicated below and, where appropriate, shall include the singular and
plural of the term defined:
"ACQUIRED ENTITIES" shall mean Value Health, the Value Health Subsidiaries
and MPN.
"ACQUIRED ENTITIES PRO FORMA BALANCE SHEET" shall have the meaning ascribed
to it in Section 3.6(d).
"ADJUSTMENT SCHEDULE" shall have the meaning ascribed to it in Section
2.3(c).
"AFFILIATE" shall mean any Person that directly, or indirectly through one
or more intermediaries, controls or is controlled by or is under common control
with the Person specified; provided that, except as used in the first sentence
of Section 9.1 (and other provisions of Article IX, to the extent affected
thereby), such term shall not be construed to include NYLIFE HealthCare
Management, Inc., a Delaware corporation, or any Person that directly, or
indirectly through one or more intermediaries, controls NYLIFE HealthCare
Management, Inc.
"AGREEMENT" shall mean this Stock Purchase Agreement, including the
exhibits and Schedules attached hereto.
"BALANCE SHEET DATE" shall mean December 31, 1997.
"BASE PURCHASE PRICE" shall mean $445,000,000.
"BOOKS AND RECORDS" shall mean all existing accounting, business,
marketing, corporate, and other files, documents, instruments, papers, books and
records, including without limitation, financial statements, budgets, ledgers,
journals, deeds, titles, policies, manuals, minute books, stock certificates and
books, stock transfer ledgers, contracts, franchises, permits, supplier lists,
reports, computer files and data, retrieval programs and operating data or
plans.
"BUSINESS DAY" shall mean a day other than Saturday, Sunday, or any day on
which the principal commercial banks located in the State of Tennessee or the
State of Missouri are authorized or obligated to close under the Laws of the
such states.
"BYLAWS" shall mean the bylaws of the relevant corporation, as amended to
the relevant date.
"CERTIFICATE OF INCORPORATION" shall mean the certificate of incorporation,
articles of incorporation, charter or similar constituent document of the
relevant corporation, as amended to the relevant date.
"CLAIM" shall have the meaning ascribed to it in Section 9.3.
"CLOSING" shall mean the consummation of the transactions contemplated by
this Agreement as provided in Article II.
"CLOSING DATE" shall have the meaning ascribed to it in Section 2.4.
"CODE" shall mean the Internal Revenue Code of 1986, as amended, and the
rules and regulations promulgated thereunder.
"COLUMBIA" shall mean Columbia/HCA Healthcare Corporation, a Delaware
corporation.
"COLUMBIA AFFILIATED GROUP" shall mean the affiliated group of corporations
(as defined in Section 1504(a) of the Code) of which Columbia is the parent.
"COMPANY" shall mean the Acquired Entities taken as a whole.
"COMPANY PLANS" shall mean each "employee benefit plan" (within the meaning
of Section 3(3) of ERISA) and each stock purchase, stock option, severance,
change-in-control, fringe benefit, bonus, incentive, deferred compensation and
other employee benefit plan, employment (including severance and change in
control) agreement, program, policy or other arrangement, whether or not subject
to ERISA (including any funding mechanism therefor now in effect or required in
the future as a result of the transactions contemplated by this Agreement or
otherwise), whether formal or informal, oral or written, under which any
employee or former employee of any Acquired Entity has any present or future
right to benefits or under which any Acquired Entity has any present or future
liability; provided, however, that "Company Plans" shall not include any
Multiemployer Plan.
"COMPANY PERMITS" shall have the meaning ascribed to it in Section 3.17.
"CONFIDENTIALITY AGREEMENT" shall mean that certain Confidentiality
Agreement, dated as of October 1, 1997, as amended by those certain addenda,
dated as of November 19, 1997, and February 10, 1998, between Columbia and
Purchaser.
"CONTRACT" shall mean any agreement, lease, sublease, license, sublicense,
promissory note, evidence of indebtedness, or other contract (whether written or
oral) to which any of the Acquired Entities is a party or by which assets of any
of the Acquired Entities are bound.
"CONTROLLED GROUP" shall have the meaning ascribed to it in Section
3.12(d).
"COURT ORDER" shall mean any judgment, order, award or decree of any
federal, state, local or other court or judicial or quasi-judicial tribunal and
any award in any binding arbitration proceeding.
"DAMAGES" shall mean any and all losses, damages, claims, costs, fines,
fees, Taxes, penalties, interest obligations and deficiencies (including,
without limitation, reasonable attorneys fees and other expenses of litigation).
"DESTRUCTION NOTICE" shall have the meaning ascribed to it in Section 6.3.
"EFFECTIVE TIME" shall have the meaning ascribed to it in Section 2.4.
"ENVIRONMENTAL CLAIM" shall mean any claim, action, cause of action,
investigation or notice (written or oral) by any person or entity alleging
potential liability (including, without limitation, potential liability for
investigatory costs, cleanup costs, governmental response costs, natural
resources damages, property damages, personal injuries or penalties) arising out
of, based on or resulting from (a) the presence, or release into the
environment, of Hazardous Substances at any location which is or has been owned,
leased, operated or utilized by the Company, or (b) circumstances forming the
basis of any violation, or alleged violation, of any Environmental Law.
"ENVIRONMENTAL LAWS" shall mean the federal, state, regional, county or
local environmental laws, regulations, ordinances, rules and policies and common
law in effect on the date hereof and as of the Effective Time relating to the
use, refinement, handling, treatment, removal, storage, production, manufacture,
transportation or disposal, emission, discharge, release or threatened release
of Hazardous Substances, or otherwise relating to protection of human health or
the environment (including, without limitation, ambient air, surface water,
ground water, land surface or subsurface strata), as the same may be amended or
modified to the date hereof and as of the Effective Time.
"ERISA" shall mean the Employee Retirement Income Security Act of 1974, as
amended.
"EXCHANGE ACT" shall mean the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.
"EXCLUDED ASSETS" shall have the meaning ascribed to it in Section 2.2.
"EXCLUDED LIABILITIES" shall mean (a) all liabilities of Value Health which
do not arise out of or relate to the business conducted by the Value Health
Subsidiaries or MPN other than those listed in SCHEDULE I(A) hereto, (b) all of
the legal proceedings listed on SCHEDULE 3.9 as being handled by Value Health,
(c) any obligations of Value Health arising out of the federal or state
securities laws and regulations and (d) all guarantees by Value Health other
than guarantees of obligations of any of the Value Health Subsidiaries.
"EXCLUDED SUBSIDIARIES" shall have the meaning ascribed to it in Section
2.2 "GAAP" shall mean accounting principles generally accepted in the United
States of America and consistently applied.
"GALEN" shall mean Galen Holdings, Inc., a Nevada corporation.
"GOVERNMENTAL AUTHORITY" shall mean any national, state or local
government, any political subdivision thereof or any other governmental,
quasi-governmental, judicial, public or statutory instrumentality, authority,
body, agency, department, bureau, commission or entity, or any arbitrator with
authority to bind a party at law.
"GROUPS" shall mean, collectively, the Columbia Affiliated Group and the
Value Health Affiliated Group.
"HAZARDOUS SUBSTANCES" shall mean any toxic or hazardous waste, pollutants
or substances, including, without limitations, friable asbestos, polychlorinated
biphenyls, petroleum products, byproducts, or other hydrocarbon substances,
substances defined or listed as a "hazardous substance," "toxic substance,"
"toxic pollutant" or similarly identified substance or mixture, in or pursuant
to any Environmental Law.
"HOLDINGS" shall mean VH Holdings, Inc., a Nevada corporation.
"HSR ACT" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and the rules and regulations promulgated thereunder.
"INDEMNIFYING PARTY" shall have the meaning ascribed to it in Section 9.3.
"INDEMNITEE" shall have the meaning ascribed to it in Section 9.3.
"INTELLECTUAL PROPERTY" shall have the meaning ascribed to it in Section
3.16.
"INTERIM PURCHASE PRICE" shall have the meaning ascribed to it in Section
2.3(b).
"KNOWLEDGE OF PURCHASER" (and any similar expression) shall mean, as to a
particular matter, the actual knowledge of any of the following officers of
Purchaser following reasonable inquiry: President and Chief Executive Officer;
General Counsel; any Executive or Senior Vice President and the Vice
President-Finance.
"KNOWLEDGE OF SELLERS" (and any similar expression, including, without
limitation, the expression "of which Sellers have Knowledge") shall mean, as to
a particular matter, the actual knowledge of any of the following officers or
their functional equivalents of the following corporations following reasonable
inquiry: (a) Columbia: Chief Executive Officer, Senior Vice President and
Controller, General Counsel, President and any Vice President; (b) Holdings:
Chief Executive Officer, General Counsel, President and any Vice President; (c)
Value Health: Chief Executive Officer, Chief Financial Officer, General Counsel,
President and any Vice President; (d) Value Rx Pharmacy Program, Inc. (a Value
Health Subsidiary): Chief Executive Officer and President; Executive Vice
President and Chief Operating Officer; President, Medication Management
Division; Senior Vice President and Chief Financial Officer; Senior Vice
President, Customer Services Division; President, Pharmaceutical Trades
Division; Senior Vice President and Chief Clinical Officer; and Vice
President-Human Relations; (e) Galen: Chief Executive Officer, General Counsel,
President and any Vice President; and (f) MPN: Chief Executive Officer, General
Counsel, President and any Vice President.
"LAWS" shall mean all statutes, laws, ordinances, regulations and other
pronouncements of any Governmental Authority having the effect of law of the
United States, any state or commonwealth of the United States, or any city,
county, municipality, department, commission, board, bureau, agency or
instrumentality thereof.
"LIABILITY THRESHOLD" shall have the meaning ascribed to it in Section
9.4(a).
"LIEN" shall mean any mortgage, pledge, assessment, security interest,
lease, sublease, lien, adverse claim, levy, charge or other encumbrance of any
kind, or any conditional sale contract, title retention contract, or other
contract to give or to refrain from giving any of the foregoing.
"MANAGEMENT LETTER AGREEMENTS" shall mean the letter agreements dated
February 18, 1998 between ValueRx Pharmacy Program, Inc. and certain employees
of the Company, which letter agreements are listed in Schedule 2.2(iv).
"MATERIAL ADVERSE EFFECT" shall mean a material adverse effect on the
assets, financial position, operations or results of operations of the Company.
"MEDMANAGEMENT" shall mean MedManagement, L.L.C., a Delaware limited
liability company, which is an Affiliate of Columbia and an Excluded Subsidiary.
"MPN" shall mean Managed Prescription Network, Inc., a Delaware
corporation.
"MPN FINANCIAL STATEMENTS" shall have the meaning ascribed to it in Section
3.6(b). "MPN SHARES" shall have the meaning ascribed to it in Section
3.2(b)(ii).
"MULTIEMPLOYER PLAN" shall mean any "multiemployer plan" within the meaning
of Section 3(37) of ERISA under which any employee or former employee of any
Acquired Entity has any present or future right to benefits or under which any
Acquired Entity or any of its subsidiaries has any present or future liability.
"NEW SAVINGS PLAN" shall have the meaning ascribed to it in Section 6.6(b).
"OTHER TAX" shall mean any tax, however denominated, including any
interest, penalties or other additions to tax that may become payable in respect
thereof, imposed by any Governmental Authority, which tax is not included within
the definition of "Tax", including, but not limited to, sales and use taxes, ad
valorem taxes, excise taxes, franchise taxes, gross receipt taxes, business
license taxes, occupation taxes and transfer taxes, and other governmental
charges, and other obligations of the same or a similar nature to any of the
foregoing.
"OUTPATIENT PHARMACY BENEFIT MANAGEMENT BUSINESS" shall have the meaning
ascribed to it in Section 3.20.
"PARTICIPANTS" shall have the meaning ascribed to it in Section 6.6(b).
"PBGC" shall mean the Pension Benefit Guaranty Corporation.
"PERMITS" shall mean all licenses, permits, franchises, rights,
registrations, approvals, authorizations, consents, waivers, exemptions,
releases, variances or orders of, or filings with, or otherwise issued by, any
Governmental Authority.
"PERMITTED LIEN" shall mean (a) any Lien approved in writing by Purchaser,
(b) any Lien for taxes or other governmental charges or assessments which are
not delinquent, (c) any Lien of any landlord, carrier, warehouseman, mechanic or
materialman and any like Lien arising in the ordinary course of business for
sums that are not delinquent, and (d) any Lien of the lessor or other financing
source on assets leased under a capitalized lease obligation.
"PERSON" shall mean any natural person, corporation, general partnership,
limited partnership, limited liability company, union, association, court,
agency, government, tribunal, instrumentality, commission, arbitrator, board,
bureau or other entity or authority.
"PRE-CLOSING PERIOD" shall have the meaning ascribed to it in Section
6.8(b)(i).
"PRELIMINARY PAYMENT AMOUNT" shall have the meaning ascribed to it in
Section 2.3(b).
"PROCEEDING" shall have the meaning ascribed to it in Section 6.8(e).
"PROHIBITED ACTIVITY" shall have the meaning ascribed to it in Section
5.16.
"PURCHASE PRICE" shall have the meaning ascribed to it in SCHEDULE I(B)
hereto.
"PURCHASE PRICE ADJUSTMENT" shall have the meaning ascribed to it in
SCHEDULE I(B).
"PURCHASER" shall mean Express Scripts, Inc., a Delaware corporation.
"PURCHASER AFFILIATED GROUP" shall mean the affiliated group of
corporations (as defined in Section 1504(a) of the Code) of which Purchaser is a
member.
"PURCHASER INDEMNITEE" shall have the meaning ascribed to it in Section
9.1.
"REAL PROPERTY" shall have the meaning ascribed to it in Section 3.18(b).
"RETURNS" shall mean all reports, estimates, declarations, schedules,
disclosures, information statements and returns relating to, or required to be
filed in connection with, any Taxes.
"SCHEDULE 2.2(IV) OBLIGATIONS" shall have the meaning ascribed to it in
SCHEDULE I(B) hereto.
"SECURITIES ACT" shall mean the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.
"SELECTED ACCOUNTING FIRM" shall mean Deloitte & Touche LLP or another
accounting firm of recognized national standing acceptable to Purchaser and
Columbia.
"SELLER GROUP" shall have the meaning ascribed to it in Section 5.16.
"SELLER INDEMNITEE" shall have the meaning ascribed to it in Section 9.2.
"SELLERS" shall mean, collectively, Columbia, Holdings and Galen.
"SHARES" shall mean the MPN Shares and the Value Health Shares.
"SPONSOR" shall have the meaning ascribed to it in Section 6.6(b).
"STRADDLE PERIOD" shall have the meaning ascribed to it in Section
6.8(b)(ii).
"TAX" or "TAXES" shall mean all federal, state and local income or profits
taxes, taxes measured by income, profits or earned surplus, payroll and employee
withholding taxes, unemployment insurance, social security taxes, and Washington
business and occupation taxes, including any interest, penalties or other
additions to tax that may become payable in respect thereof, imposed by any
Governmental Authority.
"TAX STATEMENT" shall have the meaning ascribed to it in Section
6.8(b)(ii).
"TRADEMARK ACKNOWLEDGMENT AGREEMENT" shall mean a Trademark Acknowledgment
Agreement by and among Value Health, each of the Acquired Entities and each
other subsidiary of Value Health in a form reasonably acceptable to Purchaser
and Sellers, which agreement will embody the provisions described in SCHEDULE
7.13 hereto and otherwise contain provisions customary with respect to
agreements of this type.
"TRANSFER ACCOUNTS" shall mean the checking accounts, bank accounts and
similar arrangements maintained at any financial institution and used by the
Company in connection with Columbia's cash management program; the "Transfer
Accounts" shall mean those accounts and arrangement into which the Company
deposits funds to be swept by the Columbia cash management system and not the
accounts into which the Columbia cash management system deposits funds to be
used by the Company.
"VALUE HEALTH" shall mean Value Health, Inc., a Delaware corporation.
"VALUE HEALTH AFFILIATED GROUP" shall mean the affiliated group of
corporations (as defined in Section 1504(a) of the Code) of which Value Health
was the parent for tax periods ending on or before August 5, 1997.
"VALUE HEALTH FINANCIAL STATEMENTS" shall have the meaning ascribed to it
in Section 3.6(a).
"VALUE HEALTH PRO FORMA BALANCE SHEET" shall have the meaning ascribed to
it in Section 3.6(c).
"VALUE HEALTH SHARES" shall have the meaning ascribed to it in Section
3.2(a)(ii).
"VALUE HEALTH SUBSIDIARIES" shall have the meaning ascribed to it in
Section 3.3(a).
"VALUE HEALTH SUBSIDIARY SHARES" shall have the meaning ascribed to it in
Section 3.3(d).
"VHI PLAN" shall have the meaning ascribed to it in Section 6.6(b).
"WARN ACT" shall have the meaning ascribed to it in Section 6.7.
ARTICLE II
PURCHASE AND SALE; CLOSING
2.1 Sale of the Shares. On and subject to the terms and conditions set
forth in this Agreement, at the Closing, (a) Holdings shall sell, assign,
transfer and deliver to Purchaser, free and clear of all Liens, and Purchaser
shall purchase from Holdings, the Value Health Shares, and (b) Galen shall sell,
assign, transfer and deliver to Purchaser, free and clear of all Liens, and
Purchaser shall purchase from Galen, the MPN Shares. At the Closing, title to
the Shares shall pass to Purchaser, as record and beneficial owner. Purchaser
shall then be entitled to all rights, including, without limitation, voting
rights, as the sole owner of such Shares, free and clear of all Liens.
2.2 Excluded Assets and Liabilities; Certain Included Liabilities.
Notwithstanding anything, express or implied, to the contrary contained in
Section 2.1 or elsewhere herein, the following assets and liabilities of the
Acquired Entities are to be excluded from the assets and liabilities of the
Acquired Entities being acquired by or transferred to Purchaser at Closing
through Purchaser's acquisition of the Shares: (a) all Tax accounts of the
Acquired Entities with any Governmental Authority; (b) the capital stock of, and
other equity interests owned directly or indirectly by Sellers in, each of the
corporations and other entities listed in SCHEDULE 2.2(I) (collectively, the
"Excluded Subsidiaries"); (c) all Transfer Accounts; (d) the Notes Receivable
listed in SCHEDULE 2.2(II); (e) the assets of Value Health that are listed in
SCHEDULE 2.2(III); and (f) the other assets of Value Health that are not related
to the assets or operations of the Value Health Subsidiaries and that are not
reflected on the Acquired Entities Pro Forma Balance Sheet. With the exception
of the above-described assets (the "Excluded Assets") and the Excluded
Liabilities, the Acquired Entities shall retain all of the assets and
liabilities of the Acquired Entities, including, without limitation, their
respective trade payables, operating liabilities, guarantees, accrued expenses,
contingent liabilities and other obligations. Prior to the Closing, Sellers
shall cause the Excluded Assets to be transferred to Holdings, Galen or another
Person designated by Holdings or Galen by means of dividend or otherwise. Prior
to the Closing, the Company will assume all obligations of Sellers and all
Affiliates thereof, if any, under each of the agreements and other arrangements
listed or described in SCHEDULE 2.2(IV), which agreements and arrangements
pertain to certain bonus and severance payments to which certain employees of
the Company will be entitled under the conditions set forth therein.
2.3 Purchase Price.
(a) The consideration to be paid by Purchaser for the Shares (the "PURCHASE
PRICE") shall be an amount equal to the Base Purchase Price as adjusted by the
Purchase Price Adjustment. The Purchase Price shall be allocated between the
Value Health Shares and the MPN Shares in accordance with the provisions of
SCHEDULE 2.3.
(b) For purposes of determining the amount of cash to be delivered at the
Closing in accordance with Section 2.5(b), a preliminary determination of the
Purchase Price (the "PRELIMINARY PAYMENT Amount") shall be made on or prior to
the Closing Date using the Company's then most recent monthly financial
information. Sellers shall prepare such preliminary determination and shall
deliver to Purchaser a schedule showing the calculation of the Preliminary
Payment Amount not less than two Business Days prior to the Closing Date.
(c) Within 60 days after the Closing, Columbia shall deliver to Purchaser a
schedule (the "ADJUSTMENT SCHEDULE") setting forth Sellers' determination of the
Purchase Price based upon the Company's financial data as of the Effective Time.
After the Closing, Purchaser shall (i) permit representatives of Sellers, during
normal business hours, to have reasonable access to, and to examine and make
copies of, all books and records of the Company which are in the possession of
Purchaser or the Company for purposes of preparing the Adjustment Schedule, and
(ii) cause the employees of the Company to cooperate with and assist Columbia in
the preparation of the Adjustment Schedule.
(d) Purchaser may object to any of the information or computations
contained in the Adjustment Schedule which could affect the Purchase Price. Any
such objection must be made by delivery of a written statement of objections
(stating the basis of the objections with reasonable specificity) to Columbia
within 30 days following delivery of the Adjustment Schedule to Purchaser. If
Purchaser does not so object within such 30 day period, the Adjustment Schedule,
as delivered to Purchaser, shall be considered final and binding upon the
parties. In the event Purchaser and Columbia are unable to resolve a dispute or
disagreement set forth in a written objection pursuant to this Section 2.3(d)
within 30 days of Columbia's receipt of such objection, either party may elect,
by written notice to the other party, to have all such disputes or disagreements
resolved by the Selected Accounting Firm. The Selected Accounting Firm shall
determine the Purchase Price Adjustment and calculate the Purchase Price, which
determination of the Selected Accounting Firm shall be final and binding upon
the parties. The Selected Accounting Firm shall be instructed to use every
reasonable effort to perform its services within 15 days after submission of the
Adjustment Schedule to it and, in any case, as soon as practicable after such
submission. The parties will cooperate fully with the Selected Accounting Firm,
and shall cause the Company to cooperate fully with the Selected Accounting
Firm, in connection with its determination of the Purchase Price Adjustment and
calculation of the Purchase Price. The costs and expenses for the services of
the Selected Accounting Firm shall be borne equally by Purchaser and Columbia.
(e) Within ten days after the Purchase Price shall have been agreed upon or
otherwise determined pursuant to Section 2.3(d), Columbia (on behalf of the
Sellers) or Purchaser, as appropriate, shall pay the other party cash (by wire
transfer of immediately available funds) in the amount of the difference between
the Purchase Price and the Preliminary Payment Amount, together with interest
thereon for a period from (and including) the Closing Date to (but excluding)
the date of payment, at the prime rate as quoted in the Money Rates section of
THE WALL STREET JOURNAL from time to time.
2.4 Closing. The closing of the transactions contemplated by this
Agreement (the "CLOSING") will take place at the offices of Waller Lansden
Dortch & Davis, a Professional Limited Liability Company, 511 Union Street,
Suite 2100, Nashville, Tennessee, or such other place as shall be mutually
agreed upon in writing by the parties hereto, at 10:00 a.m., Central Time, on
the earliest practicable Business Day following the satisfaction (or due waiver)
of the conditions set forth in Articles VII and VIII or such other date as may
be mutually agreed upon by the parties hereto but in no event later than the
last day of the calendar month in which such satisfaction or waiver occurs. The
date on which the Closing takes place is referred to herein as the "CLOSING
DATE." The Closing shall be deemed to occur at 11:59 p.m., Central Time, on the
Closing Date or at such other time as shall be mutually agreed upon in writing
by the parties hereto. The time at which the transactions contemplated hereby
are deemed to become effective is referred to herein as the "EFFECTIVE TIME."
2.5 Closing Deliveries. At the Closing, the following events will
occur:
(a) STOCK CERTIFICATES. Holdings will deliver to Purchaser certificates
representing the Value Health Shares and the Value Health Subsidiary Shares and
Galen will deliver to Purchaser certificates representing the MPN Shares, such
certificates representing the Shares to be duly endorsed or accompanied by duly
executed blank stock powers, as appropriate. Holdings and Galen also will
deliver to Purchaser such documentation and other information that reasonably
evidences the fact that the certificates for the Value Health Shares, the Value
Health Subsidiary Shares and the MPN Shares represent all of the issued and
outstanding shares of capital stock of each such corporation. Purchaser agrees
that, to the extent relevant, lost certificate affidavits and indemnity
agreements in form and substance reasonably satisfactory to Purchaser and
executed and delivered by Columbia shall constitute such reasonable evidence.
(b) PAYMENT FOR SHARES. At the Closing, Purchaser shall deliver the
Preliminary Payment Amount in immediately available funds by electronic wire
transfer to an account designated by Sellers.
(c) LEGAL OPINIONS.
(i) Sellers shall cause an original opinion of Waller Lansden Dortch
& Davis,a Professional Limited Liability Company, counsel for Sellers, to be
delivered to Purchaser as contemplated by Section 7.5; and
(ii) Purchaser shall cause an original opinion of Simpson
Thacher & Bartlett, counsel for Purchaser, to be delivered to Sellers as
contemplated by Section 8.5.
(d) CLOSING CERTIFICATES AND DOCUMENTS.
(i) Sellers shall deliver the other certificates and
documents required to be delivered by Sellers pursuant to Article VII; and
(ii)Purchaser shall deliver the other certificates
and documents required to be delivered by Purchaser pursuant to Article VIII.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF SELLERS
Sellers jointly and severally represent and warrant to Purchaser as
follows:
3.1 Organization of Columbia, Holdings and Galen.
(a) Columbia is a corporation duly organized,validly existing and in
good standing under the Laws of the State of Delaware.
(b) Holdings and Galen are corporations duly organized, validly
existing and in good standing under the Laws of the State of Nevada. Holdings
is a wholly-owned subsidiary of Columbia. Galen is an indirect
wholly-owned subsidiary of Columbia.
3.2 Organization and Capitalization of Value Health and MPN.
(a) VALUE HEALTH.
(i) Value Health (A) is a corporation duly organized, validly
existing and in good standing under the Laws of the State of Delaware,
(B) has the corporate power and authority to own or lease and to operate its
assets and to conduct its business as currently conducted, and (C) is duly
qualified to transact business as a foreign corporation and is in good standing
in each of the jurisdictions listed in SCHEDULE 3.2(A) and is not required to
be so qualified by the requirement of any Laws in any other jurisdiction except
where failure to be so qualified would not, either individually or in the
aggregate, have a Material Adverse Effect.
(ii) The authorized capital stock of Value Health consists of
1,000 shares of common stock, $.01 par value per share, of which 1,000 shares
(the "VALUE HEALTH SHARES") are issued and outstanding. The Value Health Shares
have been duly authorized and validly issued and are fully paid and
non-assessable.
(iii) (A) Holdings has good and marketable title to, and owns,
the Value Health Shares, beneficially and of record, (B) the Value Health
Shares are free and clear of all Liens of any nature whatsoever, (C) Holdings
has full voting power over the Value Health Shares, subject to no proxy,
shareholders' agreement, voting trust or other agreement relating to the voting
of any of the Value Health Shares, and (D) other than this Agreement, there is
no agreement between Columbia or any of its subsidiaries (including Holdings)
and any other Person with respect to the disposition of the Value Health Shares
or otherwise relating to the Value Health Shares.
(iv) (A) no Person has any preemptive right to purchase any stock
or other securities of Value Health, (B) there are no outstanding securities or
other instruments of Value Health which are convertible into or exchangeable for
any shares of its capital stock, (C) other than the Value Health Shares, there
are no outstanding securities or other instruments of Value Health giving the
owner or holder thereof the right to vote on any matters on which Value Health's
shareholders may vote, (D) there are no contracts, arrangements, commitments or
restrictions relating to the issuance, sale, transfer, purchase or obtaining of
capital stock or other securities or instruments of Value Health, and (E) there
is no existing option, warrant, right, call or commitment of any character
granted or issued by Value Health governing the issuance of shares of its
capital stock.
(b) MPN.
(i) MPN (A) is a corporation duly organized, validly existing and
in good standing under the Laws of the State of Delaware, (B) has the corporate
power and authority to own or lease and to operate its assets and to conduct
its business as currently conducted, and (C) is duly qualified to transact
business as a foreign corporation and is in good standing in each of the
jurisdictions listed in SCHEDULE 3.2(B) and is not required to be so qualified
by the requirement of any Laws in any other jurisdiction except where failure
to be so qualified would not, either individually or in the aggregate, have a
Material Adverse Effect.
(ii) The authorized capital stock of MPN consists of 1,000 shares
of common stock, $1.00 par value per share, of which 1,000 shares (the "MPN
SHARES") are issued and outstanding. The MPN Shares have been duly authorized
and validly issued and are fully paid and non-assessable.
(iii) (A) Galen has good and marketable title to, and owns,
the MPN Shares, beneficially and of record, (B) the Galen Shares are free and
clear of all Liens of any nature whatsoever, (C) Galen has full voting power
over the MPN Shares, subject to no proxy, shareholders' agreement, voting trust
or other agreement relating to the voting of any of the MPN Shares, and
(D) other than this Agreement, there is no agreement between Columbia or any of
its subsidiaries (including Galen) and any other Person with respect to the
disposition of the MPN Shares or otherwise relating to the MPN Shares.
(iv) (A) no Person has any preemptive right to purchase any stock
or other securities of MPN, (B) there are no outstanding securities or other
instruments of MPN which are convertible into or exchangeable for any shares of
its capital stock, (C) other than the MPN Shares, there are no outstanding
securities or other instruments of MPN giving the owner or holder thereof the
right to vote on any matters on which MPN's shareholders may vote, (D) there
are no contracts, arrangements, commitments or restrictions relating to the
issuance, sale, transfer, purchase or obtaining of capital stock or other
securities or instruments of MPN, and (E) there is no existing option, warrant,
right, call or commitment of any character granted or issued by MPN governing
the issuance of shares of its capital stock.
3.3 Organization and Capitalization of the Value Health Subsidiaries.
(a) SCHEDULE 3.3 contains a true, complete and correct list of all
subsidiaries, direct or indirect, of Value Health other than the Excluded
Subsidiaries (the "VALUE HEALTH SUBSIDIARIES"). Except for the Value Health
Subsidiaries and the Excluded Subsidiaries, neither Value Health nor MPN
directly or indirectly owns, of record or beneficially, any outstanding equity
interests in any corporation, partnership, joint venture or other Person.
(b) Each Value Health Subsidiary (i) is a corporation (or limited
partnership or other type of entity, as the case may be) duly organized, validly
existing and in good standing under the laws of the state of its organization,
as identified on SCHEDULE 3.3, (ii) has the corporate (or partnership or other
type of entity, as the case may be) power and authority to own or lease and to
operate its assets and to conduct its business as currently conducted, and (iii)
is duly qualified to transact business as a foreign corporation (or, if
appropriate, limited partnership or other type of entity) and is in good
standing in each of the jurisdictions listed in SCHEDULE 3.3 and is not required
to be so qualified by the requirement of any Laws in any other jurisdiction
except where failure to be so qualified would not, either individually or in the
aggregate, have a Material Adverse Effect.
(c) SCHEDULE 3.3 sets forth the authorized capital stock (or other
authorized capital) of each Value Health Subsidiary and indicates the number of
issued and outstanding shares of capital stock of such Value Health Subsidiary
(or, in the case of non-corporate Value Health Subsidiaries, the outstanding
equity issued by such Value Health Subsidiary). The shares of capital stock of
each Value Health Subsidiary have been duly authorized and validly issued and
are fully paid and non-assessable.
(d) (i) Value Health has good and marketable title to, and owns, directly
or indirectly, all of the outstanding shares of capital stock or other
outstanding equity securities of each Value Health Subsidiary (the "VALUE HEALTH
SUBSIDIARY SHARES"), beneficially and of record; (ii) the Value Health
Subsidiary Shares are free and clear of all Liens of any nature whatsoever,
(iii) Value Health has full voting power over the Value Health Subsidiary
Shares, subject to no proxy, shareholders' agreement, voting trust or other
agreement relating to the voting of any of the Value Health Subsidiary Shares,
and (iv) other than this Agreement, there is no agreement between Columbia or
any of its subsidiaries and any other Person with respect to the disposition of
the Value Health Subsidiary Shares or otherwise relating to the Value Health
Subsidiary Shares.
(e) (i) no Person has any preemptive right to purchase any stock, equity
interests or other securities of any Value Health Subsidiary, (ii) there are no
outstanding securities or other instruments of any Value Health Subsidiary which
are convertible into or exchangeable for any shares of its capital stock or any
other equity securities, (iii) other than the Value Health Subsidiary Shares,
there are no outstanding securities or other instruments of any of the Value
Health Subsidiaries giving the owner or holder thereof the right to vote on any
matters on which Value Health Subsidiary shareholders may vote, (iv) there are
no contracts, arrangements, commitments or restrictions relating to the
issuance, sale, transfer, purchase or obtaining of capital stock or other
securities or instruments of any Value Health Subsidiary, and (v) there is no
existing option, warrant, right, call or commitment of any character granted or
issued by any Value Health Subsidiary governing the issuance of shares of its
capital stock.
3.4 Corporate Authorization.
(a) The execution, delivery and performance by Sellers of this Agreement
and the other agreements to be entered into by any of them pursuant to the terms
of this Agreement, and the consummation by Sellers of the transactions
contemplated hereby and thereby are within Sellers' respective corporate powers,
are not in contravention of the terms of Sellers' respective Certificates of
Incorporation or Bylaws, and have been duly authorized and approved by the
respective boards of directors of Sellers. No other corporate proceedings on the
part of Columbia, Holdings, Galen, or any Acquired Entity are necessary to
authorize the execution, delivery and performance by Sellers or any Acquired
Entity of this Agreement or the other agreements to be entered into by any
Seller or any Acquired Entity pursuant to the terms of this Agreement.
(b) This Agreement has been duly and validly executed and delivered by
Sellers, and, as of the Closing, the other agreements to be entered into by any
Seller or any Acquired Entity pursuant to the terms of this Agreement will have
been duly and validly executed and delivered by such Seller or Acquired Entity,
as the case may be. This Agreement constitutes, and upon their execution and
delivery, such other agreements will constitute, the legal, valid and binding
obligations of Sellers and any Acquired Entity party thereto, enforceable
against Sellers and any Acquired Entity party thereto in accordance with their
respective terms (assuming the valid authorization, execution and delivery
hereof and thereof by Purchaser and any other unaffiliated third party thereto),
subject, in each case, to bankruptcy, insolvency, reorganization, moratorium and
similar laws of general application relating to or affecting creditors' rights
and to general principles of equity, including principles of commercial
reasonableness, good faith and fair dealing.
3.5 No Conflicting Agreements; Consents. Except as set forth in
SCHEDULE 3.5, neither the execution and delivery of this Agreement or any of the
other agreements to be entered into by any Seller or any Acquired Entity
pursuant to the terms of this Agreement nor the consummation of any of the
transactions contemplated hereby or thereby will:
(a) violate, conflict with, result in a breach or termination of the terms,
conditions or provisions of, constitute a default under, or entitle any party to
terminate or accelerate (i) the respective Certificates of Incorporation or
Bylaws of Columbia, Holdings, Galen or any of the Acquired Entities, (ii) any
Contract, except such violations, conflicts, breaches, defaults, terminations or
accelerations which, either individually or in the aggregate, (A) would not
materially impair the ability of the Sellers and the Acquired Entities to
perform their respective obligations hereunder or under the other agreements
contemplated hereby to be entered into by any of them or would not prevent the
consummation of the transactions contemplated hereby or thereby, or (B) would
not cause a Material Adverse Effect, (iii) any Court Order to which any Seller
or any of the Acquired Entities is a party or by which any Seller or any of the
Acquired Entities is bound, or (iv) any requirements of Law affecting any Seller
or any of the Acquired Entities, except such violations, conflicts, breaches or
defaults of such requirements of Laws which, either individually or in the
aggregate, (A) would not materially impair the ability of the Sellers and the
Acquired Entities to perform their respective obligations hereunder or under the
other agreements contemplated hereby to be entered into by any of them or would
not prevent the consummation of the transactions contemplated hereby or thereby,
or (B) would not cause a Material Adverse Effect;
(b) result in the creation or imposition of any Lien upon any of the assets
of any Acquired Entity (except for Permitted Liens); or
(c) require a permit from, the approval, consent or authorization of, or
the making by any Seller or any of the Acquired Entities of any declaration,
filing or registration with, any Governmental Authority, except as provided in
Section 5.1 or Section 6.2 and except for such approvals, consents,
authorizations, declarations, filings or registrations, the failure of which to
be obtained or made (i) would not, individually or in the aggregate, materially
impair the ability of the Sellers to perform their respective obligations
hereunder or under the other agreements contemplated hereby to be entered into
by any of them or prevent the consummation of the transactions contemplated
hereby or thereby, or (ii) would not cause a Material Adverse Effect.
3.6 Financial Statements.
(a) SCHEDULE 3.6(A) contains copies of the following: (i) the audited
combined balance sheet of the Value Health Subsidiaries (plus MedManagement) as
of December 31, 1996, (ii) the unaudited combined balance sheet of the Value
Health Subsidiaries (plus MedManagement) as of December 31, 1997, (iii) the
audited combined statements of income and cash flows of the Value Health
Subsidiaries (plus MedManagement) for the year ended December 31, 1996, and (iv)
the unaudited combined statement of income of the Value Health Subsidiaries
(plus MedManagement) for year ended December 31, 1997. Such balance sheets and
income statements are referred to as the "VALUE HEALTH FINANCIAL STATEMENTS."
The Value Health Financial Statements have been prepared from and in accordance
with the books and records of the Value Health Subsidiaries and MedManagement,
fairly present in all material respects the financial position and results of
operations of the Value Health Subsidiaries and MedManagement as of the dates
and for the periods indicated, and have been prepared in accordance with GAAP
(except as may be indicated in such Value Health Financial Statements, the notes
thereto or SCHEDULE 3.6(A) hereto).
(b) SCHEDULE 3.6(B) contains copies of the following: (i) the unaudited
balance sheet of MPN as of December 31, 1996, (ii) the unaudited balance sheet
of MPN as of December 31, 1997, (iii) the unaudited statement of income of MPN
for the year ended December 31, 1996, and (iv) the unaudited statement of income
of MPN for the year ended December 31, 1997. Such balance sheets and income
statements are referred to as the "MPN FINANCIAL STATEMENTS." The MPN Financial
Statements have been prepared from and in accordance with the books and records
of MPN, fairly present in all material respects the financial position and
results of operations of MPN as of the dates and for the periods indicated, and
have been prepared in accordance with GAAP (except as may be indicated in such
MPN Financial Statements, the notes thereto or SCHEDULE 3.6(B) hereto).
(c) SCHEDULE 3.6(C) contains copies of the following: (i) the unaudited pro
forma combined balance sheet of the Value Health Subsidiaries as of December 31,
1997, and (ii) the unaudited pro forma combined statement of income of the Value
Health Subsidiaries for the year ended December 31, 1997. Such balance sheet and
income statement are referred to as the "VALUE HEALTH PRO FORMA FINANCIAL
STATEMENTS." The Value Health Pro Forma Financial Statements have been prepared
from and in accordance with the books and records of the Value Health
Subsidiaries, fairly present in all material respects the financial position and
results of operations of the Value Health Subsidiaries as of the dates and for
the periods indicated (on a pro forma basis excluding the assets, liabilities
and income statement data of MedManagement), and have been prepared in
accordance with GAAP (except as may be indicated in such Value Health Pro Forma
Financial Statements, the notes thereto or SCHEDULE 3.6(C) hereto).
(d) SCHEDULE 3.6(D) contains a copy of the unaudited pro forma combined
balance sheet of the Acquired Entities as of December 31, 1997 (the "ACQUIRED
ENTITIES PRO FORMA BALANCE SHEET"). The Acquired Entities Pro Forma Balance
Sheet has been prepared from the books and records of the Acquired Entities,
fairly presents in all material respects the financial position of the Acquired
Entities, as of the date indicated (on a pro forma basis excluding the Excluded
Assets and the Excluded Liabilities), and has been prepared in accordance with
GAAP (except as may be indicated in such Acquired Entities Pro Forma Balance
Sheet, the notes thereto or Schedule 3.6(d) hereto).
3.7 Absence of Undisclosed Liabilities. Except as disclosed in
SCHEDULE 3.7, the Company does not have any material liabilities of any nature
(whether accrued, absolute, contingent or otherwise) except for liabilities
reflected or reserved against in the Acquired Entities Pro Forma Balance Sheet
and liabilities incurred in the ordinary course of the Company's business since
the Balance Sheet Date.
3.8 Absence of Certain Changes. Except as disclosed in SCHEDULE 3.8 or
as contemplated by Section 2.2 or Section 5.12 hereof, since the
Balance Sheet Date:
(a) neither Value Health nor MPN has declared, set aside or paid any
dividend or made or agreed to make any other distribution or payment in respect
of its capital stock or redeemed, purchased or otherwise acquired or agreed to
redeem, purchase or otherwise acquire any shares of its capital stock;
(b) the Company has not voluntarily incurred any liabilities that under
GAAP would be required to be reflected on a balance sheet for the Company (other
than current liabilities incurred in the ordinary course of its business
consistent with past practice) in an aggregate amount in excess of $500,000;
(c) the Company has not sold, assigned or transferred any of its assets or
properties except dispositions or sales of inventory or obsolete equipment in
the ordinary course of business;
(d) the Company has not mortgaged, pledged or subjected to any Lien, any of
the assets or properties of the Company other than (i) Permitted Liens, or (ii)
Liens incurred in the ordinary course of business consistent with past practice
on assets and properties of the Company having an original cost or fair value
(whichever is less) not exceeding $100,000 in the aggregate;
(e) the Company has not made or suffered any termination or amendment of
any material Contract, or canceled, waived or modified any material debts or
claims held by it, other than in the ordinary course of its business consistent
with past practice;
(f) the Company has not suffered any damage, destruction or loss, whether
or not covered by insurance, that has had or may have a Material Adverse Effect;
(g) the Company has not suffered a material adverse change in its
operations, results of operations or financial condition (it being agreed by the
parties hereto that a "material adverse change" shall not include any change
resulting from (i) changes in general conditions, including economic or
political developments, or the adoption or modification of Laws, which
conditions or Laws are generally applicable to the economy or are generally
applicable to the industries in which the Company operates; (ii) the Company's
disposition of the Excluded Assets as contemplated by this Agreement; or (iii)
the occurrence or consequence of any of the potentially adverse events or
circumstances described in SCHEDULE 3.8(G)).
(h) the Company has not made any change in its accounting principles,
practices or methodologies;
(i) the Company has not (A) made any general increase in the rate of
compensation payable to any of its employees, other than normal and customary
increases consistent with past practice or increases that otherwise were
required by the Company's obligations pursuant to applicable Law or Contracts in
effect on the Balance Sheet Date, (B) made any increase in the compensation of
any of the Company's employees whose aggregate base salary with respect to the
year ended December 31, 1997 exceeded $75,000, other than increases that were
required by the Company's obligations pursuant to Contracts in effect on the
Balance Sheet Date or (C) increased severance or termination obligations to any
of its employees (except (i) increases that are the result of increases to an
employee's underlying compensation that either (A) are not required to be
disclosed pursuant to this Section 3.8(i) or (B) are disclosed in SCHEDULE 3.8,
and (ii) increases described in or contemplated by SCHEDULE 2.2(IV) hereto);
(j) except as contemplated by SCHEDULE 2.2(IV), neither Sellers nor the
Company has entered into any employment, severance or termination agreement with
any of the employees of the Company; and
(k) neither Columbia, Holdings, Galen nor the Company has entered into any
agreement or arrangement, or made any other commitment, to do any of the
foregoing.
3.9 Legal Proceedings, etc.. There are no actions, suits or
proceedings pending, or to the Knowledge of Sellers, threatened against Columbia
or any of its subsidiaries (including Holdings, Galen or any of the Acquired
Entities) which, either individually or in the aggregate, could reasonably be
expected to, or if decided adversely, would, materially impair the ability of
Sellers or any Acquired Entity to perform their respective obligations hereunder
or under the other agreements contemplated hereby to be entered into by any of
them, or could reasonably be expected to, or if decided adversely, would,
prevent the consummation of the transactions contemplated hereby or thereby.
Except as set forth in SCHEDULE 3.9, there are no actions, suits or proceedings
pending, or to the Knowledge of Sellers, threatened against Columbia or any of
its subsidiaries (including Holdings, Galen or any of the Acquired Entities)
which, either individually or in the aggregate, could reasonably be expected to,
or if decided adversely, would, cause a Material Adverse Effect, nor is any
Acquired Entity subject to any Court Orders which, either individually or in the
aggregate, has had or may have a Material Adverse Effect. Except as otherwise
disclosed in SCHEDULE 3.9, neither Columbia, Holdings, Galen, nor any Acquired
Entity has received written notice from any Governmental Authority that any
Acquired Entity is the target of any investigation or proceeding by any
Governmental Authority, nor to the Knowledge of Sellers is any such
investigation or proceeding pending.
3.10 Certain Contracts. Except as set forth in SCHEDULE 3.10, the
Company is not in default (nor would it be in default with notice or lapse of
time or both as a result of events that have occurred) under any Contract, which
default or defaults, either individually or in the aggregate, has had or may
have a Material Adverse Effect. The Company has made available to Purchaser
customer lists and true and complete forms of all material Contracts relating to
those clients or suppliers of the Company the loss of which has had, or may
have, a Material Adverse Effect.
3.11 Title to Property. The Company is in possession of and has good
title to, or has valid leasehold interests in or valid rights under Contract to
use, all of the assets and properties used in or reasonably necessary for the
conduct of its business, including all assets and properties reflected on the
Acquired Entities Pro Forma Balance Sheet and all of the assets and properties
purchased or otherwise acquired by the Company since the Balance Sheet Date,
other than (a) assets or properties disposed of since the Balance Sheet Date in
the ordinary course of business consistent with past practice, and (b) the
Excluded Assets.
3.12 Employees; Labor Matters; Employee Benefit Plans; ERISA.
(a) Except as set forth in SCHEDULE 3.12(A) hereto, the Company is not a
party to, or bound by, any collective bargaining agreement, contract or other
agreement or understanding with a labor union or labor organization. There is no
unfair labor practice or labor arbitration proceeding pending, or to the
Knowledge of Sellers, threatened against the Company relating to its business,
except for any such proceeding which has not had, or would not reasonably be
expected to have, a Material Adverse Effect. To the Knowledge of Sellers, there
are no organization efforts with respect to the formation of a collective
bargaining unit presently being made or threatened involving employees of the
Company. There is no labor strike, material slowdown or material work stoppage
or lockout actually pending or, to the Knowledge of Sellers, threatened against
or affecting the Company, and, to the Knowledge of Sellers, the Company has not
experienced any strike, material slowdown or material work stoppage or lockout
since November 1, 1995.
(b) SCHEDULE 3.12(B) AND SCHEDULE 2.2(IV) contain a list of each (i)
Multiemployer Plan, (ii) each Company Plan that is intended to be qualified
within the meaning of Code Section 401(a) and (iii) each other material Company
Plan.
(c) With respect to each Company Plan listed in SCHEDULE 3.12(B) AND
2.2(IV), Sellers have delivered to Purchaser a current, accurate and complete
copy (or, to the extent no such copy exists, an accurate description) of each of
the following, to the extent applicable: (i) any related trust agreement or
other funding instrument; (ii) the most recent determination letter, if
applicable; (iii) any summary plan description and other material written
communications provided over the past five years by any Acquired Entity to its
employees concerning the extent of the benefits provided under such Company
Plan; and (iv) for the three most recent years (A) the Form 5500 and attached
schedules, (B) audited financial statements, (C) actuarial valuation reports and
(D) attorney's response to an auditor's request for information.
(d) Except as disclosed in SCHEDULE 3.12(D), (i) each Company Plan has been
established and administered substantially in accordance with its terms, and in
material compliance with the applicable provisions of ERISA, the Code and other
applicable laws, rules and regulations; (ii) each Company Plan that is intended
to be qualified within the meaning of Code Section 401(a) has been operated in
material compliance with such qualification provisions of the Code and has
received a favorable determination letter as to its qualification, and nothing
has occurred, whether by action or failure to act, that could reasonably be
expected to cause the loss of such qualification; (iii) no event has occurred
and no condition exists that would subject any Acquired Entity, either directly
or by reason of its affiliation with any member of its "CONTROLLED GROUP"
(defined as any organization which is a member of a controlled group of
organizations within the meaning of Code Sections 414(b), (c), (m) or (o)), to
any material tax, fine, lien, penalty or other liability imposed by ERISA, the
Code or other applicable laws, rules and regulations with respect to each
Company Plan, or any pension plan that is maintained or sponsored by a member of
the Controlled Group, that is intended to be qualified within the meaning of
Code Section 401(a), and neither have there been any reportable events,
accumulated funding deficiencies, or PBGC liens imposed with respect thereto;
(iv) for each Company Plan with respect to which a Form 5500 has been filed, no
material change has occurred with respect to the matters covered by the most
recent Form since the date thereof; (v) no "reportable event" (as such term is
defined in ERISA Section 4043) has occurred with respect to any Company Plan
that is subject to Title IV of ERISA; (vi) neither the Sellers, any of the
Acquired Entities, nor, to the Knowledge of Sellers, any other party in interest
has engaged in a "prohibited transaction" (as such term is defined in ERISA
Section 406 and Code Section 4975) with respect to any Company Plan for which
there is no exemption under ERISA Section 408 or Code Section 4975; (vii) no
"accumulated funding deficiency" (as such term is defined in ERISA Section 302
and Code Section 412 (whether or not waived)) has occurred with respect to any
Company Plan that is subject to Code Section 412; and (viii) except as required
by Title I, Part 6 of ERISA, no Company Plan provides retiree welfare benefits
and no Acquired Entity has any obligations to provide any retiree welfare
benefits.
(e) With respect to each of the Company Plans that is subject to Title IV
of ERISA, as of the Closing Date, the assets of each such Company Plan will be
at least equal in value to the then current present value of the then current
accrued benefits (vested and unvested) of the participants in such Company Plan
on a termination basis, based on the actuarial methods and assumptions reported
to the PBGC in the standard termination filing.
(f) With respect to each Multiemployer Plan, (i) neither any Acquired
Entity nor any member of their Controlled Group has incurred any withdrawal
liability under Title IV of ERISA, or to the Knowledge of Sellers would be
subject to such liability if, as of the Closing Date, any Acquired Entity or any
member of their Controlled Group were to engage in a complete withdrawal (as
defined in ERISA Section 4203) or partial withdrawal (as defined in ERISA
Section 4205) from any such Multiemployer Plan; and (ii) to the Knowledge of
Sellers no such Multiemployer Plan is in reorganization or insolvent (as those
terms are defined in ERISA Sections 4241 and 4245, respectively).
(g) With respect to any Company Plan, no actions, suits or claims (other
than routine claims for benefits in the ordinary course) are pending or, to the
Knowledge of the Sellers, threatened. Additionally, with respect to any Company
Plan, no facts or circumstances exist that reasonably could give rise to any
such actions, suits or claims that could reasonably be expected to have a
Material Adverse Effect. Neither the Sellers nor any of the Acquired Entities
has received any written or oral communication from the PBGC in respect of any
Company Plan subject to Title IV of ERISA concerning the funded status of any
such plan or any transfer of assets and liabilities from any such plan in
connection with the transactions contemplated hereby.
(h) Except as disclosed in SCHEDULE 2.2(IV), no Company Plan exists that
could result in the payment to any present or former employee of any Acquired
Entity of any money or other property or accelerate or provide any other rights
or benefits to any present or former employee of any Acquired Entity or any of
its subsidiaries as a result of the transactions contemplated by this Agreement,
whether or not such payment would constitute a parachute payment within the
meaning of Code Section 280G.
3.13 Bank Accounts. SCHEDULE 3.13 is a list of the names and locations
of all financial institutions at which any Acquired Entity maintains a checking
account, deposit account, securities account, safety deposit box or other
deposit or safekeeping arrangement (including the Transfer Accounts), the name
of the Acquired Entity that maintains each such account or arrangement and the
number or other means of identification of each such account and arrangement.
3.14 Taxes.
(a) RETURNS FILED AND TAXES PAID. Sellers or members of the Groups have
duly filed or cause to be filed, or shall duly file or cause to be filed, in a
timely manner (taking into account all extensions of due dates) with the
appropriate Governmental Authorities all Returns which are required to be filed
on or before the Closing Date by or on behalf of the Acquired Entities. All such
Returns are correct and complete in all material respects. All Taxes shown to be
due on such Returns filed prior to the date hereof have been paid in full, and
all Taxes shown to be due on such Returns filed after the date hereof will be
paid in full within the time permitted under the Code. Each of the Acquired
Entities has withheld and paid over all Taxes required to have been withheld and
paid over, and complied with all the information reporting and backup
withholding requirements, in connection with amounts paid or owing to any
employee, creditor, independent contractor or other third party. There are no
Liens on any of the assets of the Company with respect to Taxes, other than
Liens for Taxes not yet due and payable or for Taxes being contested in good
faith through appropriate proceedings.
(b) TAX DEFICIENCIES, AUDIT HISTORY. Except as set forth in SCHEDULE 3.14,
and except with respect to Tax liabilities of any member of the Columbia
Affiliated Group other than the Acquired Entities, (i) no material deficiencies
for Taxes have been claimed, proposed or assessed by any Governmental Authority
for which the Company may have any liability, (ii) there are no pending or
threatened audits, investigations or claims for or relating to any material
liability in respect of Taxes, and (iii) there are no matters under discussion
with any Governmental Authorities with respect to Taxes that may result in a
material additional amount of Taxes for which the Company may have any
liability. None of the Acquired Entities has waived any statute of limitations
in respect of Taxes or agreed to any extension of time with respect to a Tax
assessment or deficiency.
(c) FIRPTA. None of the Sellers is a "foreign person" as defined in Section
1445(f)(3) of the Code and Purchaser will not be required to withhold Tax on the
purchase of the Shares by reason of Section 1445 of the Code and the Treasury
regulations thereunder.
(d) None of the Acquired Entities has filed a consent under Code Section
341(f). Except as set forth in SCHEDULE 3.14, none of the Acquired Entities has
made any payments, is obligated to make any payments, or is a party to any
agreement that under certain circumstances could obligate it to make any
payments that will not be deductible under Code Section 280G. Except as set
forth on SCHEDULE 3.14, none of the Acquired Entities has been a member of an
affiliated group filing a consolidated federal income tax return, other than the
Columbia Affiliated Group and the Value Health Affiliated Group. None of the
Acquired Entities has any liability for the Taxes of any Person other than the
Acquired Entities or other members of the Columbia Affiliated Group under Treas.
Reg. Section 1.1502-6 (or any similar provision of state, local or foreign law),
or as a transferee or successor, pursuant to any Tax sharing agreement,
indemnification arrangement, or similar contract or arrangement, or otherwise.
3.15 Insurance. SCHEDULE 3.15 includes a list of all material insurance
policies maintained by or for the benefit of any Acquired Entity, including fire
and extended coverage and casualty, liability and other forms of insurance.
Sellers shall use commercially reasonable efforts to keep such insurance or
comparable insurance in full force and effect until the Effective Time.
3.16 Intellectual Property. Except as set forth in SCHEDULE 3.16, each
Acquired Entity owns or has the right to use (and following the Closing will
continue to own or have the right to use) all patents, trademarks, trade names,
service marks, trade secrets, copyrights and other intellectual property rights
and licenses as are necessary to conduct its business as currently conducted
(the "INTELLECTUAL PROPERTY"), free of all Liens except Permitted Liens. Except
as set forth in SCHEDULE 3.16, (a) to the Knowledge of Sellers, no infringement
exists by any of the Acquired Entities on the intellectual property rights of
any other Person that results in any way from the operations of the businesses
of the Company, except such infringements which, either individually or in the
aggregate, would not have a Material Adverse Effect, and (b) there has been no
notice for a Claim against any of the Acquired Entities that its operations,
activities or business infringe any intellectual property of any other Person.
Except as set forth in SCHEDULE 3.16, (i) no Court Orders or proceedings are
pending, or to the Knowledge of Sellers, threatened, against any of the Acquired
Entities that challenge the validity of, or such Acquired Entity's ownership of
or right to use, any of the Intellectual Property, and (ii) to the Knowledge of
Sellers, there is no infringing use of any of the Intellectual Property owned by
any Acquired Entity by any other Person. SCHEDULE 3.16(A) lists all
registrations or applications therefor with regard to Intellectual Property.
SCHEDULE 3.16(B) lists all material software used by an Acquired Entity under
license from a third party.
3.17 Compliance with Laws. The Acquired Entities hold all Permits
applicable to their respective businesses, including, without limitation,
applicable state resident and non-resident pharmacy licenses, state and federal
controlled substance permits and state insurance licenses required by applicable
Law (the "COMPANY PERMITS"), except where the failure to obtain such Permits,
either individually or in the aggregate, would not have a Material Adverse
Effect. The Acquired Entities are, and have been for the past three years, in
compliance with the terms of the Company Permits, except for such failures to
comply which, either individually or in the aggregate, would not have a Material
Adverse Effect. Except as set forth in SCHEDULE 3.17, the Acquired Entities are,
and have been for the past three years, in compliance with all Laws of any
Governmental Authority, except where the failure to comply, either individually
or in the aggregate, would not have a Material Adverse Effect.
3.18 Environmental Conditions. Except as set forth in SCHEDULE 3.18:
(a) Each of the Acquired Entities is currently, and for the prior three
years has been, in compliance with all Environmental Laws (except where failure
to be in compliance has not had or would not have a Material Adverse Effect);
(b) No Acquired Entity has stored any Hazardous Substances on any of the
real property owned or leased by it (the "REAL PROPERTY"), except in compliance
with applicable Environmental Laws (except where failure to be in compliance has
not had or would not have a Material Adverse Effect);
(c) No Acquired Entity has disposed of or released any Hazardous Substances
on any of the Real Property, except in material compliance with applicable
Environmental Laws (except where failure to be in compliance has not had or
would not have a Material Adverse Effect);
(d) No Acquired Entity has received any written communication from a
Governmental Authority or any other Person that alleges that such Acquired
Entity is not in compliance with Environmental Laws or is otherwise subject to
liability relating to Environmental Laws;
(e) There is no Environmental Claim pending or, to the Knowledge of
Sellers, threatened against any Acquired Entity; and
(f) There have been no actions, activities, circumstances, conditions,
events or incidents, including, without limitation, the release, emission,
discharge, presence or disposal of any Hazardous Substances, that reasonably
could form the basis of any Environmental Claim against any Acquired Entity,
except Environmental Claims which, either individually or in the aggregate,
would not cause a Material Adverse Effect.
3.19 Brokers. Except for Merrill Lynch & Co., neither Columbia nor any
of its subsidiaries (including any of the Acquired Entities) has paid or become
obligated to pay any fee or commission to any broker, finder or intermediary for
or on account of the transactions contemplated by this Agreement. The Acquired
Entities do not have, and following the Closing the Acquired Entities will not
have, any financial obligation to Merrill Lynch & Co. in connection with the
transactions contemplated by this Agreement.
3.20 Operations of the Acquired Entities and the Excluded Subsidiaries
(a) The Acquired Entities are engaged exclusively in the Outpatient
Pharmacy Benefit Management Business. For purposes of this Section 3.20, the
term "Outpatient Pharmacy Benefit Management Business" means any and all of the
following: (i) mail order pharmacy services, (ii) point of sale prescription
drug claims processing, (iii) formulary development or administration, (iv)
pharmacy network administration, (v) disease management services, (vi)
pharmaceuticals manufacturer research services, (vii) data analysis in
conjunction with the foregoing, and (viii) patient and client education programs
in connection with the foregoing.
(b) To the Knowledge of Sellers, none of the Excluded Subsidiaries is
engaged in the Outpatient Pharmacy Benefit Management Business, except that
certain of the Excluded Subsidiaries are engaged in activities of a nature
described in clauses (vi), (vii) and (viii) of paragraph (a) of this Section
3.20 and that certain of the Acquired Entities develop formularies in connection
with the delivery or management of health care services, but not in connection
with the activities described in clauses (i), (ii) and (iv) of paragraph (a) of
this Section 3.20.
3.21 AT&T Contract. Following the Closing, none of the Acquired Entities
shall have any obligation to utilize the Value One NET Contract Tariff (CT) No.
3602 with AT&T nor will any of the Acquired Entities suffer any penalty,
surcharge, refund liability or other financial liability as a result of not
utilizing such contract.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER
Purchaser represents and warrants to Sellers as follows:
4.1 Organization. Purchaser is a corporation duly organized, validly
existing and in good standing under the Laws of the State of Delaware.
4.2 Corporate Authorization.
(a) The execution, delivery and performance by Purchaser of this Agreement
and the consummation by Purchaser of the transactions contemplated hereby are
within Purchaser's corporate powers, are not in contravention of the terms of
Purchaser's Certificate of Incorporation or Bylaws, and have been duly
authorized and approved by the board of directors of Purchaser. No other
corporate proceedings on the part of Purchaser are necessary to authorize
Purchaser's execution, delivery and performance of this Agreement.
(b) This Agreement has been duly and validly executed and delivered by
Purchaser. This Agreement constitutes the legal, valid and binding obligation of
Purchaser, enforceable against Purchaser in accordance with its terms (assuming
the valid authorization, execution and delivery hereof by Columbia, Holdings and
Galen), subject to bankruptcy, insolvency, reorganization, moratorium and
similar laws of general application relating to or affecting creditors' rights
and to general principles of equity, including principles of commercial
reasonableness, good faith and fair dealing.
4.3 No Conflicting Agreements; Consents. Neither the execution and
delivery of this Agreement nor the consummation of any of the transactions
contemplated hereby will:
(a) violate, conflict with, result in a breach of the terms, conditions or
provisions of, or constitute a default under (i) the Certificate of
Incorporation or Bylaws of Purchaser, (ii) any agreement, lease, sublease,
license, sublicense, promissory note, evidence of indebtedness or other contract
(whether written or oral) to which assets of Purchaser are a party or by which
Purchaser is bound, except such violations, conflicts, breaches or defaults
which, either individually or in the aggregate, would not materially impair the
ability of Purchaser to perform its obligations hereunder or would not prevent
the consummation of the transactions contemplated hereby, (iii) any Court Order
to which Purchaser is a party or by which Purchaser is bound, or (iv) any
requirements of Law affecting Purchaser, except such violations, conflicts,
breaches or defaults of such requirements of Laws which, either individually or
in the aggregate, would not materially impair the ability of Purchaser to
perform its obligations hereunder or which would not prevent the consummation of
the transactions contemplated hereby; or
(b) require a permit from, the approval, consent or authorization of, or
the making by Purchaser of any declaration, filing or registration with, any
Governmental Authority, except as provided in Section 6.2 or Section 5.1 and
except for such approvals, consents, authorizations, declarations, filings or
registrations, the failure of which to be obtained or made would not, either
individually or in the aggregate, materially impair the ability of Purchaser to
perform its obligations hereunder or prevent the consummation of the
transactions contemplated hereby.
4.4 Legal Proceedings, etc.. There are no actions, suits or
proceedings pending or, to the Knowledge of Purchaser, threatened against
Purchaser which, either individually or in the aggregate, would materially
impair the ability of Purchaser to perform its obligations hereunder or could
reasonably be expected to prevent the consummation of the transactions
contemplated hereby.
4.5 Brokers. Except for BT Alex. Brown Incorporated ("BT Alex.
Brown"), Purchaser has not paid or become obligated to pay any fee or commission
to any broker, finder or intermediary for or on account of the transactions
contemplated by this Agreement.
4.6 Investment Representations.
(a) Purchaser is acquiring the Shares for its own account and not with a
view to the distribution thereof within the meaning of the Securities Act.
(b) Purchaser is not relying upon any representation or warranty of
Sellers, any of their Affiliates or any of the officers, directors, employees,
agents or representatives thereof, except for those representations and
warranties set forth in this Agreement, any other agreements contemplated
hereby, the Schedules hereto and such certificates and other instruments
required to be delivered pursuant to the terms hereof.
(c) Purchaser has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of purchasing the
Shares and to understand the risks of, and other considerations relating to, its
purchase of the Shares.
(d) Purchaser is aware that as of the Closing Date, (i) the Shares and the
Value Health Subsidiary Shares will not have been registered under the
Securities Act or any state's securities laws, and (ii) no securities issued by
any of the Acquired Entities will be subject to the reporting requirements of
the Exchange Act. Purchaser further understands that the certificates
representing the Shares and the Value Health Subsidiary Shares will include an
appropriate legend to the effect that such securities have not been registered
under the Securities Act or any state's securities laws and that such securities
may not be sold or transferred except in compliance with the Securities Act and
applicable state securities laws.
4.7 Financing. Purchaser has internally generated funds available to
be applied to the Purchase Price of not less than $100,000,000. Purchaser has
delivered to Columbia a true and correct copy of a commitment letter from
Bankers Trust Company to provide debt financing in the amount of $380,000,000 in
the aggregate to provide Purchaser with all remaining funds necessary to
consummate the transaction contemplated hereby (the "Commitment Letter").
ARTICLE V
COVENANTS OF SELLERS
5.1 Regulatory Approvals. Sellers will, and will cause the Acquired
Entities to, (a) use commercially reasonable efforts to obtain, as promptly as
practicable, each of the Permits, approvals, authorizations and clearances of
Governmental Authorities listed in SCHEDULE 5.1 hereto, and to make the filings
and declarations with Governmental Authorities listed in SCHEDULE 5.1 hereto,
(b) provide such information and communications to applicable Governmental
Authorities necessary in connection with the foregoing or in connection with the
Purchaser's obtaining any Permits, approvals, authorizations and clearances of
Governmental Authorities or making any filings or declarations with Governmental
Authorities in accordance with Section 6.2 as such Governmental Authorities or
Purchaser may reasonably request, and (c) cooperate with Purchaser in obtaining
or making, as soon as practicable, any Permits, approvals, authorizations,
clearances, filings and declarations of or with Governmental Authorities that
Purchaser is required to obtain pursuant to Section 6.2. Additionally, Sellers
will use commercially reasonable efforts to make a filing and to assist
Purchaser in making its filing, of a pre-merger notification report form
pursuant to the HSR Act on or before March 4, 1998.
5.2 Conduct Prior to the Closing. On or after the date hereof and
prior to the Closing, except as disclosed in SCHEDULE 5.2 hereto or otherwise
consented to or approved in writing by an authorized officer of Purchaser or as
contemplated by Section 2.2 or Section 5.12 of this Agreement:
(a) Sellers shall not act or omit to act, and shall cause the Acquired
Entities not to act or omit to act, otherwise than in accordance with the
following:
(i) None of the Acquired Entities shall amend its respective
Certificate of Incorporation or Bylaws (or limited partnership agreement or
other constituent document, as the case may be);
(ii) No change shall be made in the number of shares of authorized
or issued capital stock (or other authorized capital) of any of the Acquired
Entities; nor shall any option, warrants, call, right, commitment or agreement
of any character be granted or made by any of the Acquired Entities relating to
the capital stock or other securities of such Acquired Entity; nor shall any of
the Acquired Entities issue, grant or sell any securities or obligations
convertible into or exchangeable for shares of its capital stock, nor shall any
Seller enter into or permit any of the Acquired Entities to enter into any other
agreement with respect to any capital stock of such Acquired Entity or any
security convertible into or relating to any capital stock of any of the
Acquired Entities;
(iii) Neither Value Health nor MPN shall declare or pay dividends or
make any other distributions in respect of its capital stock except as provided
at Section 2.2 or 5.8;
(iv) Sellers will not change or permit any change to be made in any
accounting policy, practice or method of the Company; and
(v) The Acquired Entities will not (A) incur any indebtedness, other
than indebtedness not exceeding $500,000 in the aggregate;(B) assume, guaranty,
endorse or otherwise become liable or responsible for the obligations of any
Person other than another Acquired Entity; (C) make any loans, advances or
capital contributions to, or investments in, any other Person; or (D) make any
commitments to do any of the foregoing.
(vi) None of the Acquired Entities will make any Tax elections that
could adversely affect the Company's Tax obligations with respect to any
Post-Closing Period.
(vii) Sellers shall not, and shall not permit any of the Acquired
Entities to, settle any claim, action or proceeding if such settlement would
impose obligations or restrictions on an Acquired Entity that could result in a
Material Adverse Effect or that otherwise would subject any of the Acquired
Entities to injunctive or similar relief that would remain in effect following
the Effective Time.
(viii) None of the Acquired Entities shall enter into any Contracts
under which an Acquired Entity is to be paid on a capitated basis or would be
subject to financial risk exceeding 5% of the drug ingredient cost thereunder.
(ix) Sellers will not, and will not permit any of the Acquired Entities
to, amend or terminate any of the Management Letter Agreements or pay any of
the Schedule 2.2(iv) Obligations other than as required under the terms of
agreements and arrangements referred to in Schedule 2.2(iv) as in effect on the
date hereof (including bonus payments in respect of the year ended December 31,
1997).
(b) Sellers shall use commercially reasonable efforts not to act or omit to
act; and shall cause the Acquired Entities to use commercially reasonable
efforts not to act or omit to act, otherwise than in accordance with the
following:
(i) The business operations, activities and practices of the Acquired
Entities shall be conducted consistent with the ordinary course of business and
in conformity with past practice;
(ii) The respective business organizations of the Acquired Entities
will be preserved intact, and the services of the present employees, agents and
representatives of the Acquired Entities will be kept available for Purchaser
(except with respect to those employees or relationships terminated for cause);
and
(iii) The relationships with, and the goodwill of, the customers of the
Acquired Entities and others having business relations with the Acquired
Entities will be preserved.
5.3 Employee Matters. Pending the Closing, except as otherwise
consented to or approved in writing by an authorized officer of Purchaser or as
otherwise provided in SCHEDULE 5.3(A) hereto, Sellers will cause the Company not
to (a) make any general increase in the rate of compensation payable to any of
its employees, other than normal and customary increases consistent with past
practice or increases that otherwise may be required the Company's obligations
pursuant to Contracts or applicable Law, (b) make any increase in the
compensation (including bonus or incentive awards) of any employee whose
aggregate base salary with respect to the year ended December 31, 1997 exceeded
$75,000, (c) increase severance or termination obligations to any of its
employees (except (i) increases that are the result of increases to an
employee's underlying compensation that are permitted under this Section 5.3,
and (ii) increases described in or contemplated by SCHEDULE 2.2(IV) hereto), (d)
enter into any employment, severance or termination agreement with any of its
employees, or (e) except as contemplated by SCHEDULE 2.2(IV) hereto or Section
6.6, amend or terminate any Company Plan or adopt or enter into any new plan or
agreement that would be a Company Plan if it existed on the date hereof.
5.4 Investigation by Purchaser.
(a) Sellers will provide Purchaser and its counsel, accountants and other
representatives with reasonable access during normal business hours, to all of
the assets, properties, facilities, employees, agents, accountants and Books and
Records of any Acquired Entity and will furnish Purchaser and such
representatives during such period with all such information and data
(including, without limitation, copies of Contracts) concerning the business,
operations or affairs of any Acquired Entity in the possession of any Seller or
any Acquired Entity or under their control as Purchaser or such representatives
reasonably may request; provided, however, such investigation shall be
coordinated through either Mr. Jeffrey D. Stone, Assistant Vice President of
Columbia, or Mr. Gary Blackford, Executive Vice President and Chief Operating
Officer of ValueRx Pharmacy Program, Inc., or other persons as may be designated
in writing by Columbia for such purpose.
(b) Sellers will use commercially reasonable efforts to cause Purchaser to
be given such access to the Company's customers as Purchaser reasonably may
request; provided, however, such access shall be coordinated through Mr. Stone,
Mr. Blackford or Mr. Kevin Roberg, Chief Executive Officer of ValueRx Pharmacy
Program, Inc., or such other person as may be designated by Columbia for such
purpose and shall be implemented with one or more representatives of Columbia or
the Company.
5.5 Financial Statements and Reports. As soon as practicable following
the end of each month (and each fiscal year) from and after the date hereof and
prior to the Closing Date, Sellers will deliver to Purchaser true and complete
copies of the unaudited balance sheets and the related unaudited statements of
income of Value Health and the Value Health Subsidiaries (on a consolidated
basis) and of MPN for each month (and each fiscal year) then ended, which
financial statements shall have been prepared from and in accordance with the
Books and Records of Value Health and the Value Health Subsidiaries and of MPN,
respectively, and which shall fairly present, in all material respects, the
financial position and results of operations of Value Health and the Value
Health Subsidiaries (on a consolidated basis) and of MPN, respectively, as of
the date and for the period indicated.
5.6 Closing Conditions. Sellers will use their commercially reasonable
efforts to cause each of the conditions set forth in Article VII to be satisfied
as soon as reasonably practicable, but in all events on or prior to the Closing
Date.
5.7 Material Contracts; Transactions with Affiliates.
(a) From and after the date hereof and until the Closing, the Company shall
not, and Sellers shall not permit the Company to, enter into, become a party to,
waive any material right under or cancel, any material Contract without the
prior written consent of Purchaser, except in the ordinary course of business or
as contemplated by this Agreement. Sellers will, and will cause the Acquired
Entities to, give prompt notice to Purchaser of any of the following of which
Sellers have Knowledge: (i) any notice of, or other communication relating to,
any actual or alleged termination, or actual or threatened material default, by
any Acquired Entity subsequent to the date of this Agreement and prior to the
Closing Date under any client Contract or under any other material indenture,
instrument or agreement to which the Acquired Entity is a party or by which the
Acquired Entity is bound, (ii) any notice or other communication from any third
party alleging that the consent of such third party is or may be required in
connection with the transactions contemplated by this Agreement, or (iii) any
notice or other communication from a customer of an Acquired Entity terminating
or giving notice of any future termination of the customer's contract with the
Acquired Entity.
(b) From and after the date hereof and until the Closing, except as
expressly contemplated by this Agreement, the Acquired Entities shall not, and
Sellers shall not permit the Acquired Entities to, enter into, become a party to
or engage in any contract or transaction with any Affiliates of any of the
Acquired Entities without the prior written consent of Purchaser.
5.8 Transfer of Assets. From and after the date hereof and until the
Closing, Sellers shall cause the Company not to sell or dispose of any of its
assets or properties without the prior written consent of Purchaser, except for
(a) dispositions of the Excluded Assets as contemplated by Section 2.2, or (b)
dispositions or sales of inventory or obsolete equipment in the ordinary course
of business. Notwithstanding the foregoing or the provisions of Section
5.2(a)(iii), the Company may pay dividends or make distributions of current
assets in respect of its capital stock.
5.9 Encumbrances. From and after the date hereof and until the
Closing, Sellers shall not permit the Company to enter into or assume any
mortgage, pledge, conditional sale or other title retention agreement or permit
any Lien to attach upon any of its assets, whether now owned or hereafter
acquired, except for (i) Permitted Liens, or (ii) Liens incurred in the ordinary
course of business and in conformity with past practice on assets and properties
of the Company having an original cost or fair value (whichever is less) not
exceeding $100,000 in the aggregate.
5.10 Condition of Assets. From and after the date hereof and until the
Closing, Sellers shall use commercially reasonable efforts, and shall cause the
Company to use commercially reasonable efforts, to maintain and keep in good
order, subject to ordinary wear and tear, all leasehold improvements, inventory,
machinery, equipment and other tangible personal property owned or leased by the
Company and used in connection with the operation of the Company's business.
5.11 Consultative Process. From and after the date hereof and until the
Closing, Purchaser shall designate an individual or individuals whom Sellers may
contact during normal business hours for the purpose of approving actions or
transactions for which the consent of Purchaser is required under this
Agreement. The written approval of a designated individual as contemplated in
this Section 5.11 shall constitute the consent of Purchaser to the transaction
or action so approved. Failure of a designated individual to respond within five
Business Days of receipt of a written request for such approval (two Business
Days with respect to any approvals under clause (viii) of paragraph (a) of
Section 5.2) shall constitute the consent of Purchaser to the transaction or
action in question. Unless and until Purchaser gives written notice to the
Sellers to the contrary, such designated individuals shall be David Lowenberg,
Senior Vice President, Site Administration, and George Paz, Senior Vice
President and Chief Financial Officer.
5.12 Intercompany Accounts. Except as otherwise provided in this
Agreement, including without limitation Section 2.2, and except for amounts of a
type reflected as an account receivable or trade payable on the Acquired
Entities Pro Forma Balance Sheet, and except as otherwise provided in SCHEDULE
5.12, at or prior to the Closing, (a) all indebtedness and other amounts (i)
owed by Columbia, Holdings, Galen or any of their Affiliates (other than an
Acquired Entity) to an Acquired Entity or (ii) owed by an Acquired Entity to
Columbia, Holdings, Galen or any of their Affiliates (other than an Acquired
Entity) shall be paid, canceled or eliminated (whether or not then due), and (b)
all Liens relating to any of the aforesaid indebtedness or amounts shall be
canceled and shall be discharged of record and (c) all arrangements calling for
the transfer of funds by any Acquired Entity in connection with Columbia's cash
management program shall be terminated as of the Closing.
5.13 Notice of Certain Occurrences. Sellers will notify Purchaser
promptly in writing of, and contemporaneously will provide Purchaser with true
and complete copies of any and all material information or documents relating
to, any event, transaction or circumstance occurring of which Sellers have
Knowledge that causes or would cause any covenant or agreement of Sellers under
this Agreement to be breached, or that renders or would render untrue any
representation or warranty of Sellers contained in this Agreement as if such
representation or warranty were made on or as of the date of such event,
transaction or circumstance.
5.14 Exclusivity. From the date hereof until the earlier of the Closing
or the termination of this Agreement, Sellers agree that neither Sellers nor any
Affiliate thereof nor any of their respective officers, directors or
representatives will, (a) negotiate with any other Persons with respect to a
sale, merger, consolidation, reorganization or other business combination
pursuant to which the stock, assets or business of any Acquired Entity would be
combined with that of, or sold to, any acquirer or any other business or entity
(except as contemplated by Section 2.2); (b) solicit or respond to any offers,
bids, negotiations or inquiries with respect to the same; (c) furnish any
information with respect to the business, activities, operations, assets or
liabilities of the Company, or other similar matters, to any Persons whatsoever
(other than as described in this Agreement) with respect to the foregoing; nor
(d) proceed or continue with negotiations in respect of the foregoing which may
be in progress as of the date of this Agreement.
5.15 Resignations. Sellers shall obtain the written resignations of all
such directors and officers of the Acquired Entities as are requested by
Purchaser not less than ten days in advance of the Closing, such resignations to
be effective as of the Effective Time. To the extent that any such officer or
director is also an employee of an Acquired Entity, such resignation shall be
applicable only to the Person's position as an officer or director and not to
such Person's employment.
5.16 Post Closing Non-Competition.
(a) During the period commencing on the Closing Date and ending on the
second anniversary thereof, except to the extent permitted by paragraphs (b) and
(c) of this Section 5.16, no member of the Seller Group (which shall mean the
Sellers and their respective subsidiaries) shall, directly or indirectly, in any
form, fashion, manner or capacity, lease, own, manage, operate, control or
otherwise engage in, or be a stockholder, partner, member or holder of any other
equity interest in a Person engaged in, a Prohibited Activity anywhere within
the United States of America. For purposes of this Section 5.16, the term
"PROHIBITED ACTIVITY" shall mean the ownership or operation, directly or
indirectly, of either (i) an electronic point-of-sale pharmacy claim
adjudication system pursuant to which retail pharmacies submit outpatient
prescription drug claims for members of health plans, or (ii) an outpatient mail
service pharmacy, which, in either case, serves health plan members on a
national basis or in a service area consisting of all or parts of more than
three states. In determining whether the Seller Group is conducting either of
the businesses described in clauses (i) and (ii), operations of the types
described in clauses (i) and (ii) above that are not conducted on an integrated
or coordinated basis shall not be aggregated for purposes of determining whether
such operations are conducted on a national or multi-state basis. Therefore, by
way of example, if Seller Group owns an interest in four entities and each such
entity operates an outpatient mail service pharmacy in one jurisdiction, but
such entities' mail service pharmacies are not operated on an integrated or
coordinated basis, such operations would not constitute a Prohibited Activity.
(b) The provisions of Section 5.16(a) shall not prohibit the Seller Group
from acquiring not more than 2% of the outstanding class of any equity
securities registered under Section 12 of the Exchange Act.
(c) The provisions of Section 5.16(a) shall not prohibit the Seller Group
from acquiring the stock or assets of any Person engaged primarily in businesses
other than a Prohibited Activity; provided, however, that, if as a result of
such acquisition, the Seller Group would control the operations of any Person
that is engaged in a Prohibited Activity, the Seller Group shall divest such
Prohibited Activity within one year of such acquisition.
(d) Sellers acknowledge that the provisions of Section 5.16(a) are
reasonably necessary for Purchaser's protection and realization of the benefit
to Purchaser of its bargains under this Agreement and that a violation of
Section 5.16(a) will cause damage that may be irreparable or impossible to
quantify. Accordingly, Sellers agree that Purchaser shall be entitled to an
injunction or similar relief in equity from a court having jurisdiction to
enforce the restrictions contained in Section 5.16(a) or to restrain a violation
thereof. The right of Purchaser to such relief shall be in addition to any other
rights it may have, whether at law or in equity.
(e) In the event that a court having jurisdiction determines by final
judgment that the scope, time period or geographical area of the covenants set
forth in Section 5.16(a) are too broad to be capable of enforcement, said court
is authorized to modify said covenants and enforce such provisions as to scope,
time and geographical area as the court deems equitable. Should any portion of
Section 5.16(a) be held invalid or unenforceable, such portion shall be severed
and the remaining portions shall remain valid and enforceable.
5.17 Sellers' Non-Solicitation.
(a) During the period beginning on the date of this Agreement and ending on
the earlier of (i) one year after the Effective Time or (ii) the date on which
this Agreement is terminated, Sellers shall refrain from, either alone or in
conjunction with any other Person, or directly or indirectly through any present
or future Affiliate:
(i) employing, engaging or seeking to employ or engage any Person who
within the prior 12 months had been a key employee, manager or senior officer of
an Acquired Entity unless such key employee, manager or senior officer (A)
resigns voluntarily (without any solicitation from or on behalf of Sellers or
any of their current or future Affiliates) or (B) is terminated by an Acquired
Entity; or
(ii) causing or attempting to cause any such key employee, manager or
senior officer of an Acquired Entity to resign or sever its relationship with an
Acquired Entity.
(b) The limitations set forth in Section 5.17(a) shall not apply to any key
employee, manager or senior officer who (i) responds to an advertisement which
is placed in general circulation by or on behalf of Sellers or any of their
current or future Affiliates and which is not targeted at persons to whom
Section 5.17(a) would otherwise apply or (ii) contacts Sellers or any of their
present or future Affiliates on his or her own initiative without any direct
solicitation by Sellers or any of their present or future Affiliates.
5.18 Columbia Confidentiality Agreements. Promptly following the
execution and delivery of this Agreement, Columbia shall give written notice to
each Person (other than Purchaser) with which Columbia or any of its
subsidiaries (or any advisor on their behalf) entered into a confidentiality
agreement in connection with the proposed sale or other disposition of the
Company instructing such Person to return to the Company all information with
respect to the Company that such Person obtained in connection with its
evaluation of such proposed disposition or to destroy such information, as and
to the extent required by the applicable confidentiality agreement.
ARTICLE VI
COVENANTS OF PURCHASER; CERTAIN ADDITIONAL
COVENANTS OF THE PARTIES
6.1 Confidentiality. Purchaser acknowledges and agrees that the
Confidentiality Agreement shall survive the execution and delivery of this
Agreement by the parties hereto until the Closing shall have occurred and that
all information provided to Purchaser or its "Representatives" or "Other
Recipients" (as such terms are defined in the Confidentiality Agreement) in
accordance with this Agreement shall be considered "Evaluation Material" (as
such term is defined in the Confidentiality Agreement) except as otherwise
provided in the Confidentiality Agreement. Notwithstanding the foregoing, the
provisions of the Confidentiality Agreement set forth in SCHEDULE 6.1 hereto
shall not survive the parties execution and delivery hereof, but the deletion of
such provisions shall not affect the remainder of the Confidentiality Agreement.
6.2 Regulatory Approvals. Purchaser will (a) use commercially
reasonable efforts to obtain, as promptly as practicable, all Permits,
approvals, authorizations and clearances of Governmental Authorities listed in
SCHEDULE 6.2 hereto and to make the filings and declarations with Governmental
Authorities listed in SCHEDULE 6.2 hereto, (b) provide such information and
communications to applicable Governmental Authorities as is necessary in
connection with the foregoing or in connection with Sellers' obtaining any of
the Permits, approvals, authorizations and clearances of Governmental
Authorities or making any filings or declarations with Governmental Authorities
in accordance with Section 5.1 as such Governmental Authorities or any Seller
may reasonably request, and (c) cooperate with Sellers in obtaining or making,
as soon as practicable, any Permits, approvals, authorizations, clearances,
filings and declarations of or with Governmental Authorities that Sellers are
required to obtain or make pursuant to Section 5.1. Additionally, Purchasers
will use commercially reasonable efforts to make a filing, and to assist the
Sellers in making their filing, of a pre-merger notification report form
pursuant to the HSR Act on or before March 4, 1998.
6.3 Books and Records. Until six months after the later to occur of
(a) the final adjudication of any dispute or investigation involving Taxes
arising out of the business, operations or affairs of the Company before the
Effective Time, (b) the final adjudication of any matter for which Sellers may
be required to indemnify or hold harmless Purchaser, the Company or any
Purchaser Indemnitee pursuant to the terms of this Agreement, or (c) the running
of applicable statutes of limitations, Purchaser will maintain all Books and
Records of the Company that relate to the pre-Closing business, operations,
assets and properties of the Company, and shall give Sellers full and complete
access to all such records to the fullest extent reasonably required to enable
Sellers to satisfy their respective obligations hereunder or under applicable
law. In addition to the following, Purchaser shall not, without 90 days prior
written notification (a "DESTRUCTION NOTICE") to Sellers, destroy any
pre-Closing Books and Records of the Company. Following Sellers' receipt of a
Destruction Notice, if Sellers advise Purchaser in writing within such 90 day
period, Purchaser will promptly deliver the applicable Books and Records to
Sellers.
6.4 Closing Conditions. Purchaser will use its commercially reasonable
efforts to cause the conditions set forth in Article VIII hereof to be satisfied
as soon as reasonably practicable, but in all circumstances prior to Closing
Date.
6.5 Notice of Certain Occurrences. Purchaser will notify Sellers
promptly in writing of, and contemporaneously will provide Sellers with true and
complete copies of any and all material information or documents relating to,
any event, transaction or circumstance occurring of which Purchaser has
Knowledge that causes or would cause any covenant or agreement of Purchaser
under this Agreement to be breached, or that renders or would render untrue any
representation or warranty of Purchaser contained in this Agreement as if such
representation or warranty were made on or as of the date of such event,
transaction or circumstance.
6.6 Employee Matters.
(a) As of the Effective Time, the employees of the Company shall continue
employment with the Company in the same positions and at the same level of wages
and/or salary and without having incurred a termination of employment or
separation from service; provided, however, except as may be specifically
required by Section 6.7, by applicable law or by any Contract, the Company shall
not be obligated to continue any employment relationship with any employee for
any specific period of time. As soon as practicable after the Effective Time,
Purchaser shall provide benefits to employees of the Company which are at least
substantially comparable in the aggregate to the benefits provided to similarly
situated employees of Purchaser and its subsidiaries. To the extent any employee
benefit plan, program or policy of Purchaser or its affiliates is made available
to the employees of the Company: (a) service with the Company by any employee
prior to the Effective Time shall be credited for eligibility and vesting
purposes under such plan, program or policy, but not for benefit accrual
purposes, and (b) with respect to any welfare benefit plans to which such
employees may become eligible, Purchaser shall cause such plans to provide
credit for any co-payments or deductibles by such employees and waive all
pre-existing condition exclusions and waiting periods, other than limitations or
waiting periods that have not been satisfied under any welfare plans maintained
by the Company or its Affiliates for their employees prior to the Effective
Time.
(b) (i) Prior to the Effective Time, Columbia and Value Health shall cause
the Value Health, Inc. Retirement Savings Plan (the "VHI PLAN") to be amended to
provide that sponsorship and maintenance thereof shall be transferred to a
subsidiary of Columbia that is not an Acquired Entity (the "SPONSOR"). Columbia
shall cause the Sponsor to assume all of the obligations and liabilities of
Columbia, Value Health and their affiliates with respect to the VHI Plan and to
become responsible for all acts, omissions and transactions under or in
connection with the VHI Plan. Prior to the Effective Time, Value Health and the
Acquired Entities shall cease to sponsor, administer or contribute to the VHI
Plan and thereby cease to be responsible for any acts, omissions and
transactions under or in connection with the VHI Plan (except as provided in
(ii) below)
(ii) After the Effective Time, Value Health or one of the Acquired
Entities shall establish a new savings plan (the "NEW SAVINGS PLAN") and
associated trust to hold the assets of that plan for the participants in the
VHI Plan who are employed by the Acquired Entities immediately prior to the
Effective Time (the "PARTICIPANTS"), and shall provide to Columbia evidence
reasonably satisfactory to Columbia that the New Savings Plan and the associated
trust has been established and that the New Savings Plan qualifies under the
requirements of Section 401(a) of the Code, and that the trust is exempt from
tax under Section 401(a) of the Code. Columbia shall provide to Purchaser
evidence reasonably satisfactory to Purchaser that the VHI Plan remains
qualified under the requirements of Section 401(a) of the Code. Provided
Columbia and Purchaser have received evidence reasonably satisfactory to them in
accordance with the preceding sentences, as soon as is reasonably practicable
following the Effective Time, following receipt of such mutually satisfactory
evidence, Columbia shall take or cause to be taken all action required or
appropriate to transfer the account balances of all Participants to the trust
associated with the New Savings Plan. Such transfers shall be made in cash, or
other property acceptable to the Trustee of the New Savings Plan, in an amount
equal to the value of the account balances to be transferred, determined in a
manner that satisfies the requirements of Treas.Reg. ss.1.414(l)-1 for such a
transfer and as of the close of business on the Business Day immediately
preceding the transfer. Provided, however, that to the extent a Participant's
account balance in the VHI Plan includes one or more promissory notes evidencing
a participant loan or loans, such promissory notes shall be transferred in kind
for the Participant's credit under the New Savings Plan. For the period from the
Effective Time until the transfer, Value Health or the Acquired Entity, as the
case may be, shall collect by payroll deduction and promptly pay over to the VHI
Plan all loan payments required on participant loans made by the Plan to any
Participants and Columbia shall cause the VHI Plan to administer and pay all
distributions, withdrawals and loans payable under the terms of the respective
plan to any Participant until the transfer. Contingent upon the transfer of the
account balances to the New Savings Plan, the sponsor of the New Savings Plan
shall assume all liabilities of the Sponsor and its affiliates with respect to
the Participants under the VHI Plan and shall become, with respect to such
Participants, responsible for all acts, omissions and transactions under or in
connection with the VHI Plan.
(iii) With respect to the covenants and duties described in this
Section 6.6(b), Columbia, the Company and Purchaser shall use reasonable efforts
and shall reasonably cooperate in accomplishing the transfer of assets from the
VHI Plan to the New Savings Plan in a manner that (A) is reasonably efficient
and (B) does not result in the imposition of additional substantial burdens or
additional substantial costs on Columbia, Value Health, any Acquired Entity or
Purchaser. Nothing herein shall require Columbia to liquidate or transfer plan
assets in a manner that violates ERISA.
(c) At the Effective Time, Columbia shall make participation available to
employees of the Acquired Entities in the Company Plans which provide, on a
fully-insured basis, the life and long-term disability benefits that are in
effect with respect to employees of the Acquired Entities immediately prior to
the Effective Time. Such participation is conditioned on the timely receipt by
Columbia of written notification that Purchaser intends to continue benefits
under such Company Plans for a transition period, and receipt of Columbia of
payments from Purchaser that are sufficient to cover Columbia's out-of-pocket
expenses for extending this arrangement, including the cost of insurance
premiums, and on the ability of the employees of the Acquired Entities to
receive benefits under the applicable insurance contracts (Columbia shall use
commercially reasonable efforts to attain such coverage under such contracts).
Columbia's obligations under this paragraph shall only extend for a transitional
period of time that is appropriate to provide benefits described herein until
Purchaser can reasonably provide coverage of such employees under
(d) Purchaser shall reasonably cooperate, and shall cause the Company to
reasonably cooperate, with Columbia and its agents in providing copies of
documents and records, allowing access to documents, records and personnel, and
in sharing information which Columbia reasonably requires from time to time in
order to fulfill its obligations under ERISA and under the Company Plans, the
Multiemployer Plans, and other benefit arrangements as the administrator thereof
or in the context of the employer-employee relationship.
6.7 WARN Act Compliance. For at least 91 days following the Effective
Time, Purchaser will cause the Company to continue the employment of a legally
sufficient number of employees at each "single site of employment" (and at each
"facility" and "unit" within each "single site of employment") so that the
Company shall not be deemed to have effected a "plant closing" or "mass layoff"
under the provisions of the Worker Adjustment and Retraining Act, 29 U.S.C.
2101-2109 (the "WARN ACT"). All quoted terms used in this Section 6.7 and not
defined herein shall have the meanings ascribed to such terms under the WARN
Act.
6.8 Tax Matters.
(a) TERMINATION OF EXISTING TAX SHARING AGREEMENTS. All tax sharing
agreements or similar arrangements with respect to or involving the Acquired
Entities shall be terminated effective as of the Effective Time.
(b) PAYMENT OF TAXES.
(i) Sellers shall prepare and file, or cause to be prepared and filed,
all Returns of or which include any of the Acquired Entities (including any
amendments thereto) with respect to any taxable period ending at or prior to the
Effective Time (a "Pre-Closing Period"). Such Returns shall be prepared in a
manner consistent with past practices. Sellers shall provide Purchaser with
copies of all Returns promptly following the filing thereof. Notwithstanding
anything to the contrary in this Agreement, Sellers shall pay and indemnify and
hold Purchaser and the Acquired Entities harmless from and against (A) any and
all Taxes imposed on or with respect to any Acquired Entity for a Pre-Closing
Period (including, without limitation, any Taxes imposed on any Acquired
Entities as a result of having been (or ceasing to be) a member of the Columbia
Affiliated Group or the Value Health Affiliated Group, and any Taxes that are
determined by income or earned surplus attributable to a Pre-Closing Period),
and (B) any and all Taxes of any Person (other than the Acquired Entities) under
Treas. Reg. Section 1.1502-6 (or any similar provision of state, local or
foreign law), or as a transferee or successor, pursuant to any Tax sharing
agreement, indemnification agreement, or similar contract or arrangement, or
otherwise. Purchaser shall prepare and file, or cause to be prepared and filed,
all Returns of or which include any of the Acquired Entities, and shall pay and
shall indemnify and hold Sellers and the Groups harmless from and against all
Taxes or Other Taxes of any of the Acquired Entities for all taxable periods
other than a Pre-Closing Period, except to the extent provided in the preceding
sentence and in paragraph (ii) below.
(ii) For purposes of the immediately preceding paragraph (i) and this
paragraph (ii), if, for federal, state or local tax purposes, the taxable period
of an Acquired Entity that includes the Effective Time does not terminate at the
Effective Time (a "STRADDLE PERIOD"), the parties hereto will, to the extent
permitted by applicable law, elect with the relevant Governmental Authority to
treat a portion of any such Straddle Period as a short taxable period ending as
of the Effective Time and such short taxable period shall be treated as a
Pre-Closing Period for purposes of this Agreement. In any case where applicable
law does not permit such an election to be made then, for purposes of this
Agreement, Taxes with respect to the Acquired Entities for the Straddle Period
shall be allocated to the Pre-Closing Period using an interim
closing-of-the-books method that complies with Treasury Regulations Section
1.1502-76(b)(2)(i) (assuming that such taxable period ended at the Effective
Time) and treating such period as a Pre-Closing Period for purposes of this
Agreement, except that (A) exemptions, allowances or deductions that are
calculated on an annual basis (such as the deduction for depreciation) shall be
apportioned on a per-diem basis, and (B) real property taxes shall be allocated
in accordance with Section 164(d) of the Code. In the case of any Straddle
Period described in the preceding sentence, Purchaser shall provide Sellers and
their authorized representatives with copies of the completed Return for such
period and a statement certifying the amount of Taxes shown on such Return that
are chargeable to Sellers (the "TAX STATEMENT") at least 30 days prior to the
due date for the filing of such Return (including any extension thereof), and
Sellers and their authorized representatives shall have the right to review such
Return and Tax Statement prior to the filing of such Return. Sellers and
Purchaser agree to consult and resolve in good faith any issues arising as a
result of the review of such Return and Tax Statement by Sellers or their
authorized representatives and to mutually consent to the filing of such Return.
If the parties hereto are unable to resolve any dispute within ten business days
prior to the due date for filing of the Return in question (including any
extension thereof), the parties shall jointly request the Selected Accounting
Firm to resolve any issue in dispute as promptly as possible. If the Selected
Accounting Firm is unable to make a determination with respect to any disputed
issue prior to the due date (including extensions) for the filing of the Return
in question, the Purchaser and the Acquired Entities, as the case may be, may
file such Return without the consent of Sellers, subject, however, to the
obligation thereafter to file an amended Return reflecting the final decision of
the Selected Accounting Firm (which decision shall be rendered prior to the
expiration of the period during which an amended Return may validly be filed
with respect to the applicable taxable period). Not later than five days before
the due date (including any extensions thereof) for payment of Taxes with
respect to such Return, Sellers shall pay to Purchaser an amount equal to the
Taxes shown on the Tax Statement as being chargeable to Sellers pursuant to this
paragraph (ii). If Sellers have disputed such amount, appropriate adjustments
shall be made to the amount paid by Sellers in order to reflect the decision of
the Selected Accounting Firm in immediately available funds not later than five
days after such decision has been rendered.
(iii) Purchaser consents to the Acquired Entities joining the
consolidated Returns of the Columbia Affiliated Group for Tax periods ending at
or before the Effective Time.
(iv) In no event shall the indemnities provided for in this
Section 6.8 be subject to the provisions of Section 9.4 of this Agreement.
(c) REFUNDS AND TAX BENEFITS.
(i) Purchaser shall promptly pay to Sellers any refund or credit
(including any interest paid or credited with respect thereto) received by
Purchaser or any member of the Purchaser Affiliated Group of Taxes relating to
any Pre-Closing Period or portions of Straddle Periods at or before the
Effective Time. Purchaser shall, if Sellers reasonably so request, cause the
relevant Acquired Entity (or other relevant member of the Purchaser Affiliated
Group) to file for any refund or credit to which Seller believes it is
entitled pursuant to this Section 6.8(c). Any Proceeding with respect to such
a claim shall be governed by the provisions of this Section 6.8, including the
provisions of Section 6.8(e).
(ii) The amount of any Taxes for which indemnification is provided
under this Section 6.8 shall not be (A)increased to take account of any net Tax
cost incurred by the indemnified party arising from the receipt of indemnity
payments hereunder or (B) reduced to take account of any net Tax benefit
realized by the indemnified party arising from the incurrence or payment of any
such Taxes. Any indemnity payment under this Agreement shall be treated as an
adjustment to the Purchase Price for United State federal income tax purposes.
(iii Sellers will immediately pay to Purchaser any Tax refund (or
reduction in Tax liability) resulting from a carryback of any post-acquisition
Tax attribute of any of the Acquired Entities into the Columbia Affiliated Group
or the Value Health Affiliated Group, when such refund or reduction is realized
by the Columbia Affiliated Group or the Value Health Affiliated Group. Sellers
will cooperate with Purchaser and the Acquired Entities in obtaining such
refunds (or reduction in Tax liability), including through the filing of amended
Returns or refund claims. Purchaser agrees to indemnify Columbia for any Taxes
imposed upon any member of the Columbia Affiliated Group resulting from the
disallowance of any such carried back post-Closing Tax attribute on audit or
otherwise. Purchaser agrees that all costs and expenses incurred in connection
with any proceeding relating to Purchaser's carryback pursuant to this Section
6.8(c)(iii) shall be borne by Purchaser, and Purchaser will reimburse Columbia
for any and all reasonable direct costs and expenses incurred by any member of
the Columbia Affiliated Group in connection with any such proceeding or any such
carryback.
(d) Cooperation.
(i) Sellers, on the one hand, and Purchaser and the Acquired Entities,
on the other hand, agree to furnish or cause to be furnished to each other, upon
request, as promptly as practicable, such information and assistance (including
access to books and records) relating to the Acquired Entities as is reasonably
necessary for the preparation of any Return, claim for refund, audit or similar
matter, or the prosecution or defense of any claim, suit or proceeding relating
to any proposed adjustment of Taxes or Other Taxes.
(ii) Except as otherwise provided in Section 6.8(b)(ii), if Sellers
and Purchaser disagree as to the matters governed by this Section 6.8, Sellers
and Purchaser shall promptly consult with each other in an effort to resolve
such dispute. If any such disagreement cannot be resolved within 15 days after
eitherparty asserts in writing that such dispute cannot be resolved, the
Selected Accounting Firm shall act as an arbitrator to resolve such
disagreement. The Selected Accounting Firm's determination shall be binding and
conclusive, and any expenses relating to the engagement of such Selected
Accounting firm shall be shared equally by Sellers and Purchaser.
(e) POST-CLOSING AUDITS AND OTHER PROCEEDINGS. In the case of any audit,
examination or other proceeding ("PROCEEDING") with respect to Taxes for which
Sellers are or may be liable pursuant to this Agreement (other than a Proceeding
relating to Taxes for a Straddle Period), Purchaser shall promptly inform
Sellers, and Purchaser shall execute or cause to be executed powers of attorney
or other documents necessary to enable Sellers to take all actions desired by
Sellers with respect to such Proceeding to the extent such Proceeding may affect
the amount of Taxes for which Sellers are liable pursuant to this Agreement.
Sellers shall have the right to control any such Proceedings, (including any
Proceedings to initiate claims for refunds of or credits with respect to any
Taxes for which Sellers are liable pursuant to this Agreement and that Sellers
believe are available) including the right to initiate any claim for refund or
credit, file any amended Return or take any other action that it deems
appropriate with respect to such Taxes (or refunds or credits). All costs and
expenses incurred in connection with any such Proceeding shall be borne by
Sellers, and Purchaser and the Acquired Entities shall be reimbursed by Sellers
for any and all reasonable direct costs and expenses incurred by them in
connection with such Proceeding. Sellers will not settle any Proceeding without
Purchaser's prior written consent. In the event that Purchaser's consent is
withheld, Purchaser will assume the control, costs and expenses of the
Proceeding. If such Proceeding is ultimately resolved by payment of an amount in
excess of the amount in the original settlement proposal (or receipt of a refund
in an amount less than the amount in the original settlement proposal),
Purchaser will pay the amount of such excess (or shall pay Sellers the amount of
such refund shortfall). If such Proceeding is ultimately resolved by payment of
an amount less than the amount of the original settlement proposal (or a refund
or credit in an amount greater than the original settlement proposal) Sellers
will reimburse Purchaser for its costs and expenses to the extent of such
difference. Notwithstanding the foregoing, Sellers and Purchaser shall jointly
control all Proceedings in connection with (i) any Tax claim relating to Taxes
of any Acquired Entity for a Straddle Period and (ii) any Tax claim that could
reasonably be expected to have a material adverse effect on the business,
financial condition or results of operation of Purchaser or the Acquired
Entities for any taxable periods including or ending after the Closing Date.
6.9 Purchaser's Non-Solicitation.
(a) During the period beginning on the date of this Agreement and ending on
the earlier of (i) the Effective Time or (ii) the date that is one year after
the date on which this Agreement is terminated, Purchaser shall refrain from,
either alone or in conjunction with any other Person, or directly or indirectly
through any present or future Affiliate:
(A) employing, engaging or seeking to employ or engage any Person who
within the prior 12 months had been an officer, employee or consultant of the
Company unless such officer, employee or consultant (1) resigns voluntarily
(without any solicitation from or on behalf of Purchaser or any of its
Affiliates) or (2) is terminated by the Company; or
(B) causing or attempting to cause any officer, employee or consultant
of the Company to resign or sever a relationship with the Company.
(b) The limitations set forth in Section 6.9(a):
(i) shall apply only to (A) officers, employees and consultants who
render their services primarily at the headquarters of the Value Health
Subsidiaries (which is located at 4700 Nathan Lane North, Plymouth, Minnesota
55442), and (B) officers, employees and consultants who provide information
systems or sales services for the Company at any location; and
(ii) shall not apply to any officer, employee or consultant who (A)
responds to an advertisement which is placed in general circulation by or on
behalf of Purchaser or any of its Affiliates and which is not targeted at
persons to whom Section 6.9(a) otherwise would apply or (B) contacts Purchaser
or any of its present or future Affiliates on his or her own initiative without
any direct solicitation by Purchaser or any of its present or future Affiliates.
6.10 Financing. Purchaser agrees to promptly notify Columbia if at any
time prior to the Closing Date it becomes aware of any facts or circumstances
that cause it to conclude that it will be unable to obtain any of the financing
contemplated by the Commitment Letter substantially in accordance with the terms
described therein.
ARTICLE VII
CONDITIONS TO OBLIGATIONS OF PURCHASER
Except as may be waived by Purchaser, the obligations of Purchaser to
purchase the Shares and to consummate the transactions contemplated hereby on
the Closing Date shall be subject to the satisfaction on or prior to the Closing
Date of the following conditions:
7.1 Representations and Warranties. Except as contemplated by this
Agreement, the representations and warranties of Sellers contained in this
Agreement or in any certificate to be furnished by Sellers to Purchaser at
Closing pursuant to this Agreement shall be true on and as of the Closing Date
as though such representations and warranties were made on and as of the Closing
Date.
7.2 Compliance with Agreement. On and as of the Closing Date, Sellers
shall have performed and complied in all material respects with each covenant
and agreement required by this Agreement to be performed and complied with by
them on or before the Closing Date.
7.3 Closing Certificates. Sellers shall have delivered to Purchaser a
certificate, dated as of the Closing Date and signed on behalf of Columbia,
Holdings and Galen, respectively, by the President or Vice President of each
thereof, certifying the fulfillment of the conditions specified in Sections 7.1
and 7.2 hereof.
7.4 Secretary's Certificates. At the Closing, Purchaser shall have
received copies of the following, in each case certified as of the Closing Date
by a Secretary or an Assistant Secretary of Columbia, Holdings and Galen,
respectively:
(a) resolutions of the respective boards of directors of Columbia, Holdings
and Galen authorizing the execution, delivery and performance of this Agreement
and the other agreements that Columbia, Holdings or Galen is required to execute
and deliver pursuant to the terms of this Agreement; and
(b) the signature and incumbency of the respective officers of Columbia,
Holdings and Galen authorized to execute and deliver this Agreement and the
other agreements and certificates that Columbia, Holdings or Galen is required
to deliver on or before the Closing Date pursuant to this Agreement.
7.5 Opinion of Counsel. At the Closing, Purchasers shall have received
the opinion, dated the Closing Date, of Waller Lansden Dortch & Davis, a
Professional Limited Liability Company, counsel for Sellers, substantially to
the effect set forth in EXHIBIT 7.5 hereto. Such opinion may include
qualifications and assumptions that are customary and appropriate with respect
to the substance of such opinion.
7.6 Consents, Authorizations, Etc.. All orders, consents, Permits,
authorizations, approvals, waivers, filings, registrations and notifications of
or to Governmental Authorities set forth at SCHEDULES 5.1 AND 6.2 hereto that
are required to be obtained or given prior to the Closing shall have been
obtained or given, and all applicable waiting periods with respect thereto shall
have expired.
7.7 No Action or Proceeding. On the Closing Date, (a) no valid
judgment, order or decree of any court or other Governmental Authority
restraining, enjoining or otherwise preventing the consummation of this
Agreement or the transactions contemplated hereby shall be outstanding, and (b)
no action, suit, investigation or proceeding brought by any Governmental
Authority shall be pending before any court or other Governmental Authority or
threatened by any Governmental Authority to restrain, enjoin or otherwise
prevent the consummation of this Agreement or the transactions contemplated
hereby, which action, suit, investigation or proceeding, in the reasonable
opinion of Purchaser, may result in a decision, ruling or finding that
individually or in the aggregate has or may reasonably be expected to have a
material adverse effect on the validity or enforceability of this Agreement, or
on the ability of Purchaser to perform its obligations under this Agreement.
7.8 Certificates of Incorporation; Bylaws. Sellers shall have
delivered to Purchasers true and complete copies of the respective Certificates
of Incorporation and Bylaws of Columbia, Holdings, Galen, Value Health and MPN.
7.9 Resignation of Boards of Directors and Officers. Each then current
officer and/or member of the board of directors of any of the Acquired Entities
who is designated by Purchaser to Columbia in writing not less than ten days
prior to the Closing shall have tendered his or her written resignation as an
officer and/or director to the applicable Acquired Entity, such resignations to
be effective at or before the Effective Time. Notwithstanding the foregoing, no
such officer or director shall be required to resign as an employee of the
Company.
7.10 Good Standing Certificates. At the Closing, Sellers shall have
delivered to Purchaser good standing certificates issued with respect to
Columbia, Holdings, Galen and each of the Acquired Entities issued by the
Secretary of State of the relevant entity's state of incorporation. Each such
good standing certificate shall be dated as of a date that is not more than ten
days prior to the Closing Date.
7.11 Material Adverse Change. No change or event shall have occurred
that has caused a Material Adverse Effect. The parties agree that the foregoing
shall not include any change resulting from, (a) changes in general conditions
(including economic or political conditions) or the adoption or modification of
Laws, which conditions or Laws are generally applicable to the economy or are
generally applicable to the industries in which the Company operates, (b) the
Company's disposition of the Excluded Assets as contemplated by this Agreement,
or (c) the occurrence or consequences of any of the potentially adverse events
or circumstances described in SCHEDULE 7.11.
7.12 Waiver of Conditions. Purchaser may waive any condition of this
Article VII to the extent permitted by applicable law. Except as otherwise
provided herein, the consequences of any knowing waiver shall be (a) the
elimination of the waived condition as a valid basis for Purchaser to refuse to
close the transactions contemplated by this Agreement, and (b) the release of
Columbia, Holdings and Galen from any claim by Purchaser for resulting injuries
and Damages with respect to that waived condition.
7.13 Trademark Acknowledgment Agreement. The Trademark Acknowledgment
Agreement shall have been executed and delivered by the parties thereto, and a
copy of such executed Trademark Acknowledgment Agreement shall have been
delivered to Purchaser.
7.14 Columbia PBM Agreement. Columbia and an Acquired Entity shall have
executed and delivered an agreement in form and substance reasonably
satisfactory to Purchaser and Columbia that will embody the provisions described
in SCHEDULE 7.14 and otherwise contain provisions customary with respect to
agreements of this type.
7.15 Financing. Purchaser shall have received the debt financing
contemplated by the Commitment Letter substantially in accordance with the terms
described therein.
7.16 MedManagement Agreement. MedManagement and the appropriate
Acquired Entity shall have executed and delivered an agreement in form and
substance reasonably satisfactory to Purchaser and Columbia that will embody the
provisions described in SCHEDULE 7.16 and otherwise contain provisions customary
with respect to agreements of this type.
ARTICLE VIII
CONDITIONS TO OBLIGATIONS OF SELLERS
Except as may be waived in writing by Sellers, the obligations of Sellers
to consummate the transactions contemplated hereby on the Closing Date shall be
subject to the satisfaction on or prior to the Closing Date of the following
conditions:
8.1 Representations and Warranties. Except as contemplated by this
Agreement, the representations and warranties of Purchaser contained in this
Agreement or in any certificate to be furnished by Purchaser to Sellers at
Closing pursuant to this Agreement shall be true on and as of the Closing Date
as though such representations and warranties were made on and as of the Closing
Date.
8.2 Compliance with Agreement. On and as of the Closing Date,
Purchaser shall have performed and complied in all material respects with each
covenant and agreement required by this Agreement to be performed and complied
with by it on or before the Closing Date.
8.3 Closing Certificates. Purchaser shall have delivered to Sellers a
certificate, dated as of the Closing Date and signed on behalf of Purchaser by
the President or a Vice President thereof, certifying the fulfillment of the
conditions specified in Sections 8.1 and 8.2 hereof.
8.4 Secretary's Certificate. At the Closing, Sellers shall have
received copies of the following, in each case certified as of the Closing Date
by a Secretary or an Assistant Secretary of Purchaser:
(a) resolutions of the board of directors of Purchaser authorizing the
execution, delivery and performance of this Agreement and the other agreements
that Purchaser is required to execute and deliver pursuant to the terms of this
Agreement;
(b) the signature and incumbency of the officers of Purchaser authorized to
execute and deliver this Agreement and the other agreements and certificates
that Purchaser is required to deliver on or before the Closing Date pursuant to
this Agreement.
8.5 Opinion of Counsel. At the Closing, Sellers shall have received
the opinion, dated the Closing Date, of Simpson Thacher & Bartlett, counsel for
Purchaser, substantially to the effect set forth in EXHIBIT 8.5 hereto. Such
opinion may include qualifications and assumptions that are customary and
appropriate with respect to the substance of such opinion.
8.6 Consent, Authorizations, Etc.. All orders, consents, Permits,
authorizations, approvals, waivers, filings, registrations and notifications of
or to Governmental Authorities set forth at SCHEDULES 5.1 AND 6.2 hereto that
are required to be obtained or given prior to the Closing shall have been
obtained or given, and all applicable waiting periods with respect thereto shall
have expired.
8.7 No Action or Proceeding. On the Closing Date, (a) no valid
judgment, order or decree of any court or other Governmental Authority
restraining, enjoining or otherwise preventing the consummation of this
Agreement or the transactions contemplated hereby shall be outstanding, and (b)
no action, suit, investigation or proceeding brought by any Governmental
Authority shall be pending before any court or other Governmental Authority or
threatened by any Governmental Authority to restrain, enjoin or otherwise
prevent the consummation of this Agreement or any of the transactions
contemplated hereby, which action, suit, investigation or proceeding, in the
reasonable opinion of Columbia, may result in a decision, ruling or finding that
individually or in the aggregate has or may reasonably be expected to have a
material adverse effect on the validity or enforceability of this Agreement or
on the ability of Columbia, Holdings or Galen to perform their respective
obligations under this Agreement.
8.8 Good Standing Certificate. At the Closing, Purchaser shall have
delivered to Sellers a good standing certificate issued with respect to
Purchaser by the Secretary of State of Purchaser's state of incorporation. Such
good standing certificate shall be dated as of a date that is not more than ten
days prior to the Closing Date.
8.9 Certificate of Incorporation; Bylaws. Purchaser shall have
delivered to Sellers true and complete copies of Purchaser's Certificate of
Incorporation and Bylaws.
8.10 Waiver of Conditions. Sellers may waive any conditions of this
Article VIII to the extent permitted by applicable law. Except as otherwise
provided herein, the consequences of any knowing waiver shall be (a) the
elimination of the waived condition as a valid basis for Sellers to refuse to
close the transactions contemplated by this Agreement, and (b) the release of
Purchaser from any claim by Sellers for resulting injuries and Damages with
respect to that waived condition.
8.11 Trademark Acknowledgment Agreement. The Trademark Acknowledgment
Agreement shall have been executed and delivered by the parties thereto.
8.12 MedManagement Agreement. MedManagement and the appropriatecquired
Entity shall have executed and delivered an agreement in form and substance
reasonably satisfactory to Purchaser and Columbia that will embody the
provisions described in SCHEDULE 7.16 and otherwise contain provisions customary
with respect to agreements of this type.
ARTICLE IX
INDEMNIFICATION
9.1 Indemnification by Sellers. Subject to the provisions of this
Article IX, Sellers shall indemnify and hold harmless Purchaser, any Affiliate
of Purchaser, the respective officers, directors, shareholders, employees,
agents and representatives of Purchaser and its Affiliates, and each such
Person's respective successors and assigns (each, a "PURCHASER INDEMNITEE") from
and after the Effective Time from and against the Excluded Liabilities and any
Damages incurred or suffered by such Purchaser Indemnitee as a result of or
arising from (a) any inaccuracy in any of the representations and warranties
made herein by Sellers, (b) any breach of any of the covenants or agreements
made herein by Sellers, (c) the claims, actions, suits, and other proceedings
listed in SCHEDULE 9.1(C), (d) the payment obligations of Value Health under the
agreements listed on SCHEDULE 9.1(D), and (e) any claims, actions, suits or
other proceedings arising out of any of the Excluded Liabilities.
9.2 Indemnification by Purchaser. Purchaser shall indemnify and hold
harmless each Seller, any Affiliate of any Seller (other than an Affiliate
providing insurance coverage with respect to any claim by Purchaser under this
Agreement), the respective officers, directors, shareholders, employees, agents
and representatives of each Seller and their respective Affiliates, and each
such Person's respective successors and assigns (each a "SELLER INDEMNITEE")
from and after the Effective Time from and against any Damages incurred or
suffered by such Seller Indemnitee as a result of, or arising from (a) any
inaccuracy in any of the representations and warranties made herein by
Purchaser, (b) any breach of any of the covenants or agreements made herein by
Purchaser, (c) any breach of any of the covenants or agreements made by
Purchaser in the Confidentiality Agreement, including any use of the Evaluation
Material by Purchaser or its Representatives or Other Recipients contrary to the
terms of the Confidentiality Agreement, (d) any claims, actions, suits, or other
proceedings relating to the operations of the Company after the Effective Time,
(e) any claims, actions, suits or proceedings arising out of any post-Closing
obligation or action on the part of the Company under any Contract which is not
an Excluded Liability, and (f) the claims, actions, suits and other proceedings
listed in SCHEDULE 9.2(F).
9.3 Claims Procedures. Unless a different procedure is specified in
Section 6.8, in the case of any Damages for which indemnification is sought
hereunder, the party seeking indemnification (the "INDEMNITEE") shall promptly
notify the party from whom indemnification is sought (the "INDEMNIFYING PARTY")
in writing of the existence and nature of such Damages, as well as the claim,
demand, action or proceeding, if any, out of which the Damages arise (a
"CLAIM"); provided, however, that no failure or delay by the Indemnitee in the
performance of the foregoing shall reduce or otherwise affect the obligation of
the Indemnifying Party to indemnify and hold the Indemnitee harmless, except to
the extent the Indemnitee's failure to give or delay in giving the required
notice materially impairs the Indemnifying Party's ability to indemnify or
defend or to mitigate its Damages, in which case the Indemnifying Party shall
have no obligation to indemnify the Indemnitee to the extent of Damages, if any,
caused by such failure to give or delay in giving the required notice. If such
Damages arise out of a Claim by a third person, the Indemnitee must give the
Indemnifying Party a reasonable opportunity to defend the same or prosecute such
action to conclusion or settlement satisfactory to the Indemnifying Party at the
Indemnifying Party's sole cost and expense and with counsel of its own
selection, and the Indemnifying Party shall pay any resulting settlements
(including all associated Damages), satisfy any judgments or comply with any
decrees; provided, further, however, that the Indemnitee shall at all times also
have the right fully to participate in the defense at Indemnitee's sole cost and
expense so long as such participation occurs without hindering or impairing the
defense of the Indemnifying Party. Notwithstanding the foregoing, without the
prior written consent of the Indemnitee, the Indemnifying Party shall not
compromise or settle any Claim if (i) the terms thereof impose any liability or
obligations on the Indemnitee, or (ii) the terms thereof fail to include an
unconditional general release of the Indemnitee with respect to all liabilities
and obligations in respect of such Claim. If the Indemnifying Party shall,
within a reasonable time after said notice, fail to defend, the Indemnitee shall
have the right, but not the obligation, and without waiving any rights against
the Indemnifying Party, to undertake the defense of, and with the consent of the
Indemnifying Party (such consent not to be withheld unreasonably), to compromise
or settle the Claim on behalf, for the account, and at the risk and expense, of
the Indemnifying Party and shall be entitled to collect the amount of any
settlement or judgment or decree and all costs and expenses (including, without
limitation, reasonable attorney's fees) in connection therewith from the
Indemnifying Party. Except as provided in the preceding sentence, the Indemnitee
shall not compromise or settle any Claim.
9.4 Limitations on Claims.
(a) LIABILITY THRESHOLDS. Notwithstanding anything in this Article IX to
the contrary, no indemnified Damages with respect to Claims arising out of a
breach of Sellers' representations and warranties shall be payable pursuant to
this Article IX unless and until the aggregate amount of indemnified Damages
asserted against Sellers under this Article IX with respect to such Claims
equals or exceeds $2,600,000 (the "LIABILITY THRESHOLD"). Once the Liability
Threshold for such Claims has been reached, the Indemnitee shall be entitled to
the benefit of the indemnity under this Article IX for such Claims to the extent
of any and all Damages above the Liability Threshold up to, but not exceeding,
an amount equal to the Purchase Price.
(b) SUBROGATION. Following indemnification as provided for hereunder, the
Indemnifying Party shall be subrogated to all rights of the Indemnitee with
respect to all Persons relating to the matter for which indemnification has been
made.
(c) SURVIVAL OF CERTAIN REPRESENTATIONS, WARRANTIES AND COVENANTS;
LIMITATION OF TIME TO BRING CLAIMS.
(i) The representations and warranties set forth in this Agreement
shall survive the Closing and shall expire eighteen months after the Effective
Time. No Claim for indemnification arising out of a breach of such
representations and warranties may be brought after that time.
(ii) In addition to the other limitations set forth in this
Section 9.4, no Claim for indemnification may be brought under this Article IX
later than the earlier of(A) one year following the date on which the Indemnitee
receives actual notice of the inaccuracy, breach, claim, action, suit or other
proceeding forming the basis of the Claim, and (B) the applicable statute of
limitations with respect to such Claim.
(d) NO LIABILITY THRESHOLD. Notwithstanding anything in this Article IX to
the contrary (including, without limitation, the Liability Threshold or any
other limitation set forth in this Section 9.4), Sellers' obligation to
indemnify Purchaser with respect to Excluded Liabilities shall extend to all
Damages asserted against Sellers with respect to such claims.
9.5 Insured Losses. The amount of any Damages for which
indemnification is provided under this Article IX shall be net of any
duplicative amounts recovered by the Indemnitee under insurance policies or from
unaffiliated third Persons with respect to such Damages.
ARTICLE X
TERMINATION
10.1 Termination Events. This Agreement may be terminated at any time
prior to Closing upon prior written notice by the party electing to terminate
this Agreement to the other party:
(a) by mutual agreement of Columbia and Purchaser (expressed in writing);
(b) by either Columbia or Purchaser if any permanent injunction, Court
Order or other order, decree or ruling of any court or other Governmental
Authority of competent jurisdiction permanently restraining, enjoining or
otherwise preventing the consummation of the transactions contemplated hereby
shall have been issued and become final and non-appealable;
(c) by either Columbia or Purchaser if the Closing shall not have occurred
by June 30, 1998; provided, however, that the right to terminate this Agreement
under this Section 10.1(c) shall not be available to any party whose breach of
its representations and warranties in this Agreement or whose failure to perform
any of its covenants and agreements under this Agreement shall have been a
contributing cause of, or resulted in, the failure of the Closing to occur on or
before such date;
(d) by Columbia upon a breach in any material respect of any covenant or
agreement on the part of the Purchaser set forth in this Agreement, or if any
representation or warranty of the Purchaser shall have been breached or shall
have become untrue, in any such case that the conditions set forth in Sections
8.1 and 8.2 would be incapable of being satisfied by June 30, 1998 (or any later
date as such date may be otherwise extended by mutual agreement of the parties);
or
(e) by Purchaser upon a breach in any material respect of any covenant or
agreement on the part of any Seller set forth in this Agreement, or if any
representation or warranty of any Seller shall have been breached or shall have
become untrue in any such case such that the conditions set forth in Sections
7.1 and 7.2 would be incapable of being satisfied by June 30, 1998 (or any later
date as such date may be otherwise extended by mutual agreement of the parties).
10.2 Effect of Termination. In the event of termination of this
Agreement pursuant to Section 10.1, all obligations of the parties hereto shall
terminate, except the obligations of the parties pursuant to Sections 6.1, 6.9
and 12.1 and except for the provisions of this Section 10.2 and Sections 12.2,
12.6, 12.7, 12.8, 12.9, 12.10 and 12.13. Moreover, in the event of termination
of this Agreement pursuant to Section 10.1(c), (d) or (e), nothing herein shall
prejudice the ability of the non-breaching party from seeking damages from any
other party for any breach of this Agreement, including without limitation,
attorneys' fees and the right to pursue any remedy at law or in equity.
ARTICLE XI
NOTICES
11.1 Notices. All notices and other communications hereunder shall be
in writing and shall be deemed to have been duly given when delivered in person
or received by telegraphic or other electronic means (including facsimile,
telecopy and telex) or when delivered by overnight courier, or if mailed, five
days after being deposited in the United States mail, certified or registered
mail, first-class postage prepaid, return receipt requested, to the parties at
the following addresses or facsimile numbers:
If to Columbia, Holdings or Galen, to:
Columbia/HCA Healthcare Corporation
One Park Plaza
Nashville, Tennessee 37203
Attention: General Counsel
Fax: (615) 344-1859
With copies to:
Columbia/HCA Healthcare Corporation
One Park Plaza
Nashville, Tennessee 37203
Attention: Senior Vice President - Development
Fax: (615) 344-2128
and
G. Scott Rayson
Waller Lansden Dortch & Davis,
A Professional Limited Liability Company
511 Union Street, Suite 2100
Nashville, Tennessee 37219-1760
Fax: (615) 244-6804
If to Purchaser, to:
Express Scripts, Inc.
14000 Riverport Drive
Maryland Heights, Missouri 63043
Attention: Thomas M. Boudreau,
Senior Vice President
and General Counsel
Fax:
With a copy to:
Richard A. Garvey
Simpson Thacher & Bartlett
425 Lexington Avenue
New York, New York 10017
Fax: (212) 455-2502
Any party from time to time may change its address or facsimile number for
the purpose of receipt of notices to that party by giving a similar notice
specifying a new address or facsimile number to the other notice parties listed
above in accordance with the provisions of this Section 11.1.
ARTICLE XII
MISCELLANEOUS
12.1 Fees and Expenses. Except as otherwise provided in this Agreement,
the Sellers shall pay their own expenses (including, without limitation, the
fees and expenses of Merrill Lynch & Co. in connection with this Agreement and
also including those expenses of the Acquired Entities in connection with this
Agreement and the transactions contemplated hereby incurred prior to the
Effective Time) and Purchaser shall pay its own expenses (including, without
limitation, the fees and expenses of BT Alex Brown in connection with this
Agreement, and also including those of the Acquired Entities in connection with
this Agreement and the transactions contemplated hereby incurred after the
Effective Time) in connection with this Agreement and the transactions
contemplated hereby. Columbia and Purchaser each shall pay one half all
recording fees, transfer fees, transfer taxes, and documentary or stamp taxes,
if any, relating to the sale and the transactions provided for herein. Except as
set forth in the following sentence, each party shall pay its own fees and
expenses, including counsel fees and filing fees, with respect to the
preparation and filing of its notifications under the HSR Act. Further, and
notwithstanding the foregoing, Purchaser will bear all reasonable costs and
expenses, including attorneys' fees of all parties, resulting from or relating
to any investigation or challenge of the transactions contemplated hereby
initiated by the United States Federal Trade Commission, the United States
Department of Justice or the Attorney General of any state on, prior to or after
the Closing under antitrust or similar laws, including reasonable costs and
expenses resulting from or relating to any "second request" issued in connection
with the parties' HSR Act filings made in connection with the transactions
contemplated hereby.
12.2 Entire Agreement. Except for documents and agreements executed
pursuant hereto, and except for the provisions of the Confidentiality Agreement
(which Confidentiality Agreement shall survive the parties' execution and
delivery of this Agreement and the other documents and agreements contemplated
hereby until the Closing shall have occurred, except to the extent otherwise
provided in Section 6.1), this Agreement supersedes all prior oral discussions
and written agreements between the parties with respect to the subject matter of
this Agreement (including any term sheet or similar agreement or document
relating to the transactions contemplated hereby). Except for the
Confidentiality Agreement, this Agreement, including the exhibits and schedules
hereto and other documents delivered in connection herewith, contains the sole
and entire agreement between the parties hereto with respect to the subject
matter hereof.
12.3 Waiver. Any term or condition of this Agreement may be waived at
any time by the party which is entitled to the benefit thereof. Any such waiver
must be in writing and must be duly executed by such party. A waiver on one
occasion shall not be deemed to be a waiver of the same or any other breach,
provision or requirement on any other occasion.
12.4 Amendment. This Agreement may be modified or amended only by a
written instrument duly executed by each of the parties hereto.
12.5 Counterparts; Facsimile Signatures. This Agreement may be executed
simultaneously in any number of counterparts, each of which shall be deemed an
original, but all of which shall constitute one and the same instrument.
Facsimile signatures on this Agreement shall be deemed to be original signatures
for all purposes.
12.6 No Third Party Beneficiary. The terms and provisions of this
Agreement are intended solely for the benefit of Sellers, Purchaser and their
respective successors or assigns, and it is not the intention of the parties to
confer third party beneficiary rights upon any other Person.
12.7 GOVERNING LAW, CONSTRUCTION. THIS AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TENNESSEE APPLICABLE
TO A CONTRACT EXECUTED AND PERFORMED IN SUCH STATE. The parties hereto agree
that no provisions of this Agreement or any related document shall be construed
for or against or interpreted to the advantage or disadvantage of any party
hereto by any court or other Governmental Authority by reason of any party's
having or being deemed to have structured or drafted such provision, each party
having participated equally in the structuring and drafting hereof.
12.8 Binding Effect. This Agreement shall be binding upon and inure to
the benefit of the parties and their respective successors and permitted
assigns, including successors by merger or otherwise.
12.9 No Assignment. Neither this Agreement nor any right hereunder or
part hereof may be assigned by any party hereto without the prior written
consent of the other parties hereto; PROVIDED, HOWEVER, that Columbia, Holdings
and Galen, on the one hand, and Purchaser, on the other hand, may assign their
respective rights and obligations under this Agreement to other Persons who (a)
are wholly-owned (directly or indirectly) by Columbia or Purchaser,
respectively, and (b) agree to be bound by the terms and conditions of this
Agreement. Notwithstanding the assignment of this Agreement or any rights or
obligations hereunder, the assignor shall be jointly and severally liable with
its assignee for its obligations hereunder.
12.10 Headings, Gender, Etc.. The headings used in this Agreement have
been inserted for convenience and do not constitute provisions to be construed
or interpreted in connection with this Agreement. Unless the context of this
Agreement otherwise requires, (a) words of any gender will be deemed to include
each other gender, (b) words using the singular or plural number also will
include the plural or singular number, respectively, (c) the terms "hereof",
"herein", "hereby" and derivative or similar words will refer to this entire
Agreement, and (d) the terms "Article," "Section," "Schedule" and "Exhibit" will
refer to the specified Article or Section of this Agreement or the specified
Schedule or Exhibit to this Agreement.
12.11 Public Announcement. On or before the Closing, the parties hereto
will each consult with one another prior to making or issuing public statements
or announcements with respect to this Agreement or the transactions contemplated
hereby and will use good faith efforts to agree on the text of a joint public
statement or announcement and/or will use good faith efforts to obtain the other
parties' approval of the text of any public statement or announcement to be made
solely on behalf of a party; provided that the foregoing shall not preclude any
party from making such disclosure as may be required by applicable Law or the
rules of any securities exchange or market on which securities of such party are
listed or quoted.
12.12 Access to Information. Sellers and Purchaser agree that, from time
to time after the Closing, upon the reasonable request of another party hereto,
they will cooperate and will cause their respective Affiliates to cooperate with
each other to effect the orderly transition of the business, operations and
affairs of the Company. Without limiting the generality of the foregoing, (a)
Sellers will give and will cause their Affiliates to give representatives of the
Company reasonable access to all Books and Records of Sellers reasonably
requested by the Company or Purchaser in the preparation of any post-Closing
financial statements, reports or Tax returns of the Company; and (b) Purchaser
will give and will cause the Company to give representatives of Sellers
reasonable access to all pre-Closing Books and Records of the Company reasonably
requested by Sellers in the preparation of any post-Closing financial
statements, reports or Tax returns of Sellers.
12.13 Severability; Invalid Provisions. If any provision of this
Agreement is held to be illegal, invalid or unenforceable under any present or
future law, (a) such provisions will be fully severable; (b) this Agreement will
be construed and enforced as if such illegal, invalid or unenforceable provision
had never comprised a part hereof; (c) the remaining provisions of this
Agreement will remain in full force and effect and will not be affected by the
illegal, invalid or unenforceable provision or by its severance herefrom; and
(d) in lieu of such illegal, invalid or unenforceable provision, there will be
added automatically as a part of this Agreement a legal, valid and enforceable
provision as similar in terms to such illegal, invalid or unenforceable
provision as may be possible.
12.14 Cooperation. Upon request, each of the parties hereto shall
cooperate with the other in good faith, at the requesting party's expense, in
furnishing information, testimony and other assistance in connection with any
actions, proceedings, arrangements, or disputes involving any of the parties
hereto (other than in a dispute among such parties or entities) and based upon
contracts, arrangements or acts of Columbia, Holdings, Galen, or the Company
which were in effect or occurred prior to the Effective Time and which relate to
the business of the Company. Purchaser shall cause the Company to provide any
information or documents reasonably requested by Columbia, Holdings or Galen in
connection with tax or other disputes, settlements, investigations, proceeding
or other matters in respect of any period ending at or prior to the Effective
Time. The party requesting documents or information pursuant to this Section
shall pay all fees and expenses paid to unaffiliated third parties by the party
providing such documents or information in connection with providing such
information or document. In addition, following the Closing, the parties hereto
shall cooperate fully with each other and make available to the other, as
reasonably requested, and to any taxing authority, all information, records,
documents relating to tax liabilities or potential tax liabilities and tax bases
of the Company, and shall preserve all such information, records and documents
at least until the expiration of any applicable statute of limitations or
extensions thereof. Purchaser agrees that to the extent reasonably requested by
Columbia, Purchaser will permit each of the Persons who is a party to a
Management Letter Agreement to furnish information, testimony and other
assistance to, and to otherwise cooperate with, Sellers in connection with
Purchaser's obligations under this Section 12.14.
12.15 Further Assurance Clause. On and after the Closing Date, Sellers,
the Company and Purchaser will take all appropriate action and execute all
documents, instruments or conveyances of any kind which may be reasonably
necessary or advisable to carry out any of the provisions hereof, including,
without limitation, putting Purchaser in possession and operation control of the
business of the Company.
IN WITNESS WHEREOF, the parties have caused this Stock Purchase Agreement
to be executed as of the date first above written.
COLUMBIA/ HCA HEALTHCARE CORPORATION
By: /s/ V. Carl George
Name: V. Carl George
Title:
VH HOLDINGS, INC.
By: /s/ V. Carl George
Name: V. Carl George
Title:
GALEN HOLDINGS, INC.
By: /s/ V. Carl George
Name: V. Carl George
Title:
EXPRESS SCRIPTS, INC.
By: /s/ Barrett Toan
Name: Barrett Toan
Title:
<PAGE>
INDEX OF
SCHEDULES AND EXHIBITS TO THE
STOCK PURCHASE AGREEMENT BY AND AMONG
COLUMBIA/HCA HEALTHCARE CORPORATION, VH HOLDINGS, INC.,
GALEN HOLDINGS, INC. AND EXPRESS SCRIPTS, INC.
I(a Exclusions From "Excluded Liability"
I(b) Purchase Price Adjustments
2.2(i) Excluded Subsidiaries
2.2(ii) Notes Receivable
2.2(iii) Excluded Assets
2.2(iv) Employee Obligations
2.3 Allocation of Purchase Price
3.2(a) Value Health Jurisdictions
3.2(b) MPN Jurisdictions
3.3 Value Health Subsidiaries
3.5 Seller Exceptions to Agreements; Conflicts
3.6(a) Value Health and Value Health Subsidiaries (plus MedManagement)
Financial Statements
3.6(b) MPN Financial Statements
3.6(c) Value Health Pro Forma Financial Statements
3.6(d) Acquired Entities Pro Forma Balance Sheet
3.7 Liabilities Not Disclosed in Financial Statements
3.8 Transactions Outside the Ordinary Course of Business
3.8(g) Material Adverse Changes
3.9 Legal Proceedings
3.10 Certain Contracts
3.12(a) Labor Matters
3.12(b) Company Plans and Multiemployer Plans
3.12(d) Company Plan Compliance
3.13 Bank Accounts
3.14 Tax Matters
3.15 Insurance Policies
3.16 Intellectual Property
3.16(a) Registrations and Applications
3.16(b) Material Software Licenses
3.17 Compliance Exceptions
3.18 Environmental Conditions
5.1 Seller Regulatory Approvals
5.2 Conduct Prior to Closing
5.3(a) Employee Matters
5.12 Intercompany Accounts
6.1 Confidentiality
6.2 Purchaser Regulatory Approvals
7.5 Opinion of Sellers' Counsel
7.11 Material Adverse Change
7.13 Trademark Acknowledgment Agreement Provisions
7.14 Columbia PBM Agreement
7.16 MedManagement Agreement Provisions
8.5 Opinion of Purchaser's Counsel
9.1(c) Claims, Actions, Suits and Other Proceedings
9.1(d) Value Health Payment Obligations
9.2(f) Purchaser Indemnification of Suits
<PAGE>
Schedule I(b)
PURCHASE PRICE ADJUSTMENTS
A. DEFINITIONS. For purposes of this SCHEDULE I(B), (a) capitalized terms
used herein but not defined herein shall have the meanings ascribed to them in
the Agreement, and (b) the following defined terms shall have the meanings
indicated below:
"Beginning Adjusted Working Capital" shall mean the working
capital of the Acquired Entities as reflected in the Acquired Entities
Pro Forma Balance Sheet, subject to the following adjustments: (a) any
current or deferred income taxes that are reflected on the Acquired
Entities Pro Forma Balance Sheet shall be excluded from the calculation
of Beginning Adjusted Working Capital, (b) any portion of the Schedule
2.2(iv) Obligations that are reflected as a liability on the Acquired
Entities Pro Forma Balance Sheet shall be excluded from the calculation
of Beginning Adjusted Working Capital, and (c) the Reserves shall be
excluded from the calculation of Beginning Adjusted Working Capital.
The calculation of Beginning Adjusted Working Capital is set forth in
EXHIBIT A hereto.
"Closing Adjusted Working Capital" shall mean the working
capital of the Acquired Entities as reflected in the Closing Balance
Sheet, subject to the following adjustments: (a) any current or
deferred income taxes that are reflected on the Closing Balance Sheet
shall be excluded from the calculation of Closing Adjusted Working
Capital, (b) any portion of the Schedule 2.2(iv) Obligations that are
reflected as a liability on the Closing Balance Sheet shall be excluded
from the calculation of Closing Adjusted Working Capital, and (c) the
Reserves less the Reserve Payment Amount shall be excluded from the
calculation of Closing Adjusted Working Capital.
"Closing Balance Sheet" shall mean the unaudited pro forma
combined balance sheet of the Acquired Entities as of the Effective
Time, which balance sheet will be prepared on a consistent basis with
the Acquired Entities Pro Forma Balance Sheet.
"Purchase Price Adjustment" shall mean the adjustment to the
Base Purchase Price calculated in accordance with the provisions of
Paragraph B of this SCHEDULE I(B).
"Reserves" shall mean the reserves listed in EXHIBIT B hereto.
"Reserves Payment Amount" shall mean the aggregate amount
spent by the Company between the Balance Sheet Date and the Effective
Time with respect to the Reserves, regardless of the amount spent,
individually or in the aggregate, with respect to any or all of the
Reserves.
"Schedule 2.2(iv) Obligations" shall mean the obligations of
the Acquired Entities under (i) each of the bonus, severance and other
arrangements described in item 17 of SCHEDULE 2.2(IV) to the Agreement
and (ii) the 1997 Bonus Plan payments for ValueRx employees as
described in Attachment 1 to SCHEDULE 2.2(IV), in each case, including
any related payroll taxes.
"Schedule 2.2(iv) Obligations Payment Amount" shall mean the
amount of the Schedule 2.2(iv) Obligations paid by Sellers or the
Acquired Entities between the Balance Sheet Date and the Effective
Time.
B. PURCHASE PRICE ADJUSTMENT CALCULATION. The Purchase Price Adjustment
shall be the sum of the following adjustments to the Base Purchase Price:
1. The Base Purchase Price shall be increased (or decreased) by the amount
by which the Closing Adjusted Working Capital is greater than (or less than) the
Beginning Adjusted Working Capital.
2. The Base Purchase Price shall be increased by the Schedule 2.2(iv)
Obligations Payment Amount.
3. The Base Purchase Price shall be increased by the Reserves Payment
Amount.
4. The Base Purchase Price shall be decreased by an amount equal to the sum
of the Schedule 2.2(iv) Obligations Payment Amount and the Reserves Payment
Amount, multiplied by .33.
5. The Base Purchase Price shall be decreased by the amount of any proceeds
from the Company's sale of 20,203 shares of capital stock of Stadtlanders Drug
Company, Inc. that are distributed to the Sellers.
<PAGE>
EXHIBIT A
TO
SCHEDULE I(B)
<TABLE>
<CAPTION>
DECEMBER 31, 1997
<S> <C>
------------------
Total current assets excluding any deferred $193,823,948
income taxes per Acquired Entities Pro Forma
Balance Sheet
Less current liabilities per Acquired Entities (191,290,966)
Pro Forma Balance Sheet
Exclude Schedule 2.2(iv) Obligations reflected 2,058,003
on the Acquired Entities Balance Sheet
Exclude Reserves reflected in Exhibit B 35,637,926
----------
Adjusted Working Capital $40,228,911
</TABLE>
<PAGE>
EXHIBIT B
TO
SCHEDULE I(B)
HUSKIE CASH PURCHASE RESERVES ANALYSIS
I. Necessary Cash Reserves
<TABLE>
<CAPTION>
12/31/97 Adjusted
Item Balance Adjustments Balance
<S> <C> <C> <C>
- ------------------------------------------------------ -------------------- --------------------- -------------------
A) Severance/consultants/termination/outplacement $ 3,990,651 $ 3,990,651
B) Lease termination fees 821,096 821,096
C) Lease FMV 2,982,533 $ 217,467 3,200,000
D) Medintell shutdown 4,655,793 4,655,793
E) Legal entity dissolution 96,070 96,070
F) Storage termination costs (115,250) 160,250 45,000
G) Davenport building FMV 576,072 576,072
H) Accrual adjustments (203,875) 203,875 -
I) DEA reserve 1,218,000 1,218,000
J) Pharmacy network repricing 1,645,000 1,645,000
K) Legal accrual 2,000,000 2,000,000
L) Performance guarantees 1,000,000 1,000,000
M) Foxmeyer dispute 1,500,000 1,500,000
N) CPS consolidation expenses 897,635 462,365 1,360,000
O) CPS exit costs at mail facility (87,950) 87,950 -
P) Rx Net consolidation 4,359,579 4,359,579
Q) H.I.D. consolidation 4,797,248 4,797,248
R) CPS consolidation/tandem conversion 2,587,030 2,587,030
S) APS consolidation 204,000 204,000
T) Purchase related costs prior to closing 675,837 675,837
U) Costs of administering purchase accounting (17,935) 34,935 17,000
V) Financial systems shutdown (772,912) 825,912 53,000
W) I/S termination fees and exit costs 148,188 148,188
X) Retail systems consolidation 106,260 106,260
Y) Accrued vacation on exited facilities 450,000 450,000
Z) Exit CPS on-line reference system 64,594 64,594
AA) Columbia DEA licensing 67,508 67,508
BB) Printed materials (1,120,948) 1,120,948 -
-------------------- --------------------- -------------------
$32,524,224 $3,113,702 $35,637,926
-------------------- --------------------- -------------------
</TABLE>
II. Balance Sheet Reserves
<TABLE>
<CAPTION>
12/31/97 Adjusted
Item Balance Adjustments Balance
<S> <C> <C>
- ---------------------------------------- -------------------------------- ------------------------ ------------------
A) Formulary reserve $4,600,000 $4,600,000
B) Contract dispute reserve 2,000,000 2,000,000
C) NJ Medicaid reserve 2,000,000 2,000,000
D) Inventory reserve 750,000 750,000
E) H.I.D. A/R reserve 500,000 500,000
-------------------------------- ------------------
$9,850,000 $9,850,000
-------------------------------- ------------------
</TABLE>
